Podcasts about medicine dentistry

This podcast will give you an updated approach to the original podcast on the evaluation of stridor. In this episode, listeners will 1) define stridor and the pathophysiology causing stridor, 2) create a differential diagnosis based on a patient's presenting signs and symptoms, 3) differentiate benign causes of stridor from those that are life-threatening, 4) describe common pathogens involved in infectious etiologies of stridor, and 5) outline a basic management plan for a patient with stridor based on the differential diagnoses and investigative findings. The podcast was created by Taylor Dennison, a fourth-year medical student at the University of Saskatchewan, in collaboration with Dr. Gerdung, a pediatric respirologist and sleep specialist for Alberta Health Services, and Dr. Melanie Lewis, a general pediatrician at the Stollery Children's Hospital and professor of pediatrics and chief wellness officer for the Faculty of Medicine & Dentistry at the University of Alberta.

This podcast reviews the topics covered in the CPS position statement about Adverse Childhood Experiences (ACEs), early relational health, and their implications for clinical practice. Listeners will learn about ACE and their impacts on health, utilizing early relational health as an avenue to protect against the negative effects of ACEs, and how clinicians can work with families to promote early relational health and optimize parenting for healthy child development. It was written by Andrea Moir, a third-year medical student at the University of British Columbia and Dr. Mel Lewis, a professor in the Department of Peds and the Chief Wellbeing Officer in the Faculty of Medicine & Dentistry at the University of Alberta.

In episode 44 we have a chat to JP Leach who is a Professor of Clinical Neurology and Honorary Professor within The School of Medicine Dentistry and Nursing at The University of Glasgow. JP is the head of undergraduate medical programmes at The University, so naturally we get stuck into conversations about about medical education, curriculum development, neuro anatomy and of course, the one thing everyone wants to talk to him about - his background in stand up comedy!

Guests: Dr. Grace Parraga, Tier 1 Canada research chair in lung imaging at Western University's Schulich School of Medicine & Dentistry, and Dr. Michael Nicholson, a respirologist with the post-acute COVID-19 program at St. Joseph's Hospital in London, Ont. An estimated one in ten COVID survivors suffer from long COVID. The cause of the condition has puzzled doctors and long COVID sufferers are frustrated by the lack of knowledge and support. With an estimated 200 symptoms associated with long COVID, it's hard to diagnose and treat. Now, an Ontario research team has made a discovery that could be key in helping to diagnose it and potentially find treatments. This episode was produced by Alexis Green, Matthew Hearn and Raju Mudhar.

Most of us would like to ‘write better', but few of us make intentional efforts to improve. Lorelei Lingard is internationally known for her efforts to help health researchers and clinical scholars become better writers. In this podcast we talk about her Writers Studio courses and her book “Story, not Study”, 30 Brief Lessons to Inspire Health Researchers as Writers. Lorelei Lingard has a ‘day job' as Professor in the Department of Medicine, and Senior Scientist at the Centre for Education Research & Innovation, both at the Schulich School of Medicine & Dentistry at Western University in Canada. With a PhD in Rhetoric, she studies the communication practices of clinical teams, and evidence-based educational initiatives to improve teamwork.  She received the Karolinska Prize for Research in Medical Education in 2018. In this conversation, she shares details of her training in rhetoric, her transition to working in health professions education, and her joy she finds in coaching relationships as a writing mentor. We spoke about the Writer's Craft - a transformative series of articles on better academic writing - written by Lorelei and her colleague Chris Watling (also an HMI alumnus). Each article offers a succinct pearl: Mastering the sentence, Enlisting the power of the verb, Get control of your commas, and many more. Building on this series and their coaching work, the duo has now produced “Story, not Study”, 30 Brief Lessons to Inspire Health Researchers as Writers. If you've never considered your writing voice, whether you paragraph strategically, or how you approach academic hedging, this is a great place to start.   Lorelei also shared her thoughts on reading habits (she thinks Margaret Atwood is good, but not great

Welcome back peeps to another episode of the Tooth or dare Podcast! We are grateful to have Dentsply Sirona as this weeks' sponsor.  The Nupro Freedom Cordless Prophy System from Dentsply Sirona is ergonomically designed to reduce strain and musculoskeletal disorders. We both use the Nupro Freedom along with the splatter-free (and gluten-free!) Nupro prophy paste in our practices. The comfortable and quiet Nupro Freedom is the best option for keeping our patients and our wrists happy. The removable and autoclavable outer sheath, the 20 unique disposable angles, and the increased maneuverability make this a must-have tool in the hands of dental hygienists.  Get your Nupro Freedom Cordless Prophy System today at the Dentsply Sirona website. https://www.dentsplysirona.com/en-us/categories/preventive/nupro-polishing.html  Ask your local sales rep if they have a demo unit to use, perhaps this may help you convince the peeps in the practice with buying power!    This week Irene and Katrina interview Dr. Dave Shirazi whose bio speaks for itself. Irene had a hard time getting to all the details because of her spotty internet situation but here it is!    Dr. Shirazi graduated from Howard University College of Dentistry, in Washington D.C. in 2000 and earned a Masters's degree in Oriental Medicine from SAMRA University in 2006 and is also a board-licensed Acupuncturist. He has completed over 2000 hours of continuing education in TMD and facial pain, craniomandibular orthopedics, and sleep-disordered breathing. He has also completed a hospital mini-residency in oriental medicine at the China Beijing International Acupuncture Training Centre which is the only organization the World Health Organization (WHO) has authorized to teach internationally on acupuncture and herbology, and another at Kyung Hee University and Medical Center, the top medical hospital and medical research school in Korea. From 2011 through 2016, he became a board-licensed RPSGT, the first and so far only, dual degreed dentist and RPSGT. He is the founder of the Bite, Breathe and Balance Podcast, dedicated to the multidisciplinary approach to treating craniofacial pain and sleep disorders in adults and children. Dr. Shirazi is the director of state-of-the-art private practices, The TMJ and Sleep Therapy Centre of Conejo Valley and Los Angeles, that are limited to the treatment of TMD, craniofacial pain, Sleep breathing disorders, and craniomandibular orthopedics. His practice is part of the TMJ and Sleep Therapy Centre international family, one of over 65 Centres throughout the world, and is located in the beautiful hills of Thousand Oaks and Brentwood CA. Personally, Dr. Shirazi enjoys hiking and camping in the state parks, travelling, and speaking. He is married to the love of his life Kimberly Shirazi and has welcomed their first son, Maximus. They live in the Santa Monica Mountains, where they are very close to nature. Disclosures: Typically part of a clinical research study, My Sleep Lab conducts research for multiple industries including pharmaceutical industry Adjunct Board supporter, lecturer, AACP Private Practice   This episode had a lot of great takeaways related to TMD pain, Oriental Medicine vs Western Medicine and fun facts about what really happens behind the doors of an endo office.  Find Dr. Dace Shirazi  On Facebook here  Send him an email at daveshirazi@yahoo.com  or on his website http://www.sleepconejo.com/shirazi/ ___________________________________________________ Our hosts encourage you to leave them a review! LET'S GO! Find more of our episodes at https://www.toothordare.ca/ Follow us on Instagram! Podcast IG: @toothordare.podcast Irene: @toothlife.irene Katrina: @thedentalwinegenist

Here’s why eating garlic and onions can prevent hypertension and diabetes Federal University of Technology (Nigeria), April 16, 2021 n a recent study, researchers at the Federal University of Technology in Nigeria investigated the benefits of eating garlic, white onion and purple onion against serious conditions like diabetes and hypertension. They confirmed these by looking at how extracts from the three alliums affect the activity of diabetes-related enzymes, such as a-amylase and a-glucosidase, and the hypertension-related enzyme, angiotensin-converting enzyme (ACE). The researchers reported their findings in an article published in the Journal of Dietary Supplements. Garlic, white onion and purple onion show antioxidant, antidiabetic and antihypertensive properties Garlic and onions are spices commonly used in cooking. They also serve as ingredients in several traditional delicacies in Nigeria that are known to contain plenty of polyphenols. To assess the beneficial properties of garlic, white onion and purple onion, the researchers first obtained extracts from each and assessed their inhibitory effects on certain enzymes. They also conducted assays to determine the antioxidant capacities of the extracts. ACE is the enzyme responsible for converting angiotensin I into angiotensin II, the hormone that increases blood pressure, as well as body water and sodium content. Angiotensin II elevates blood pressure by constricting the blood vessels; hence, chemicals that can inhibit the activity of ACE, which is responsible for the production of angiotensin II, are used for the treatment of hypertension. (Related: Meet the “two-day cure” plant: An African medicinal plant that can naturally lower blood pressure.) a-Amylase is the enzyme that breaks down starch and glycogen into glucose and maltose (two glucose molecules bound together). In humans, this enzyme is produced by the salivary glands and the pancreas. a-Glucosidase, on the other hand, is responsible for breaking down carbohydrates in the small intestine and facilitating the absorption of glucose. Inhibiting the activity of this enzyme is one of the strategies currently used to prevent the rise of blood sugar levels following a carbohydrate-filled meal. The researchers reported that the garlic, purple onion and white onion extracts inhibited the activities of ACE, a-amylase and a-glucosidase in vitro in a concentration-dependent manner. At a half maximal inhibitory concentration (IC50) of 0.59 mg/mL, the purple onion extract exhibited a higher inhibitory effect on ACE than the white onion extract (IC50 = 0.66 mg/mL) and the garlic (IC50 = 0.96 mg/mL) extract. Meanwhile, the white onion extract showed a significantly stronger inhibitory effect on a-amylase at an IC50 of 3.93 mg/mL than the garlic extract (IC50 = 8.19 mg/mL) and the purple onion (IC50 = 8.27 mg/mL) extract. The garlic extract, on the other hand, showed a similar inhibitory effect (IC50 = 4.50 mg/mL) on a-glucosidase as the white and purple onion extracts. All three extracts also showed dose-dependent free radical scavenging activity and reducing power in the antioxidant assays. Based on these findings, the researchers concluded that garlic, white onion and purple onion can be used to treat or prevent diabetes and hypertension, thanks to their ability to inhibit ACE, a-amylase and a-glucosidase activity, as well as lipid peroxidation in the pancreas and the heart.   Adolescents with lack of empathy show early signs of psychopathy   University of Coimbra (Portugal), April 14, 2021 A pioneering study with the Portuguese population shows that adolescents with high levels of callous-unemotional traits demonstrate lower levels of anticipated guilt towards the possibility of committing an immoral act and struggle to judge an immoral act as a wrong one. Researchers have evaluated the callous traits, that is, the lack of empathy and disregard for the wellbeing and feelings of others, of 47 adolescents between 15 and 18 years old. The teenagers watched video animations portraying examples of moral transgressions, such as incriminating someone or keeping money that fell from someone else's pocket. "This approach allowed us to create more realistic scenarios that happen in daily life," explains Oscar Gonçalves, a neuroscientist at Proaction Lab and co-author of the study. The adolescents were asked how guilty they would feel if they were the ones to commit the moral transgressions and how wrong they think the actions were.  Although the callous-unemotional traits in adolescents are known to be precursors of psychopathy in adulthood, the results of the study differ from what is known about psychopaths. "Adults with psychopathic traits show low levels of anticipated guilt but consider immoral actions as wrong. However, in our study, adolescents with high CU levels show levels of guilt and judge immoral actions as less wrong," explains Margarida Vasconcelos, first author.  However, researchers have found evidence of a dissociation between moral emotions and moral judgment, that is, between the feelings of guilt and the judgment of immoral actions. "Even in adolescents with sub-clinical levels of callous-unemotional traits, this dissociation typical in psychopathy in adulthood is already happening during development," explains the study coordinator Ana Seara Cardoso.  The results of the study will "contribute to the development of a severe anti-social behavior model" and allow the "development of intervention targets, rehabilitation and early prevention of anti-social behavior," says Ana Seara Cardoso.   Omega-3 supplements do double duty in protecting against stress   Ohio State University, April 20, 2021 A high daily dose of an omega-3 supplement may help slow the effects of aging by suppressing damage and boosting protection at the cellular level during and after a stressful event, new research suggests. Researchers at The Ohio State University found that daily supplements that contained 2.5 grams of omega-3 polyunsaturated fatty acids, the highest dose tested, were the best at helping the body resist the damaging effects of stress. Compared to the placebo group, participants taking omega-3 supplements produced less of the stress hormone cortisol and lower levels of a pro-inflammatory protein during a stressful event in the lab. And while levels of protective compounds sharply declined in the placebo group after the stressor, there were no such decreases detected in people taking omega-3s. The supplements contributed to what the researchers call stress resilience: reduction of harm during stress and, after acute stress, sustained anti-inflammatory activity and protection of cell components that shrink as a consequence of aging. The potential anti-aging effects were considered particularly striking because they occurred in people who were healthy but also sedentary, overweight and middle-aged—all characteristics that could lead to a higher risk for accelerated aging. "The findings suggest that omega-3 supplementation is one relatively simple change people could make that could have a positive effect at breaking the chain between stress and negative health effects," said Annelise Madison, lead author of the paper and a graduate student in clinical psychology at Ohio State. The research is published today (Monday, April 19, 2021) in the journal Molecular Psychiatry. Madison works in the lab of Janice Kiecolt-Glaser, professor of psychiatry and psychology and director of the Institute for Behavioral Medicine Research at Ohio State. This paper is a secondary analysis of one of Kiecolt-Glaser's earlier studies showing that omega-3 supplements altered a ratio of fatty acid consumption in a way that helped preserve tiny segments of DNA in white blood cells. Those short fragments of DNA are called telomeres, which function as protective caps at the end of chromosomes. Telomeres' tendency to shorten in many types of cells is associated with age-related diseases, especially heart disease, and early mortality. In the initial study, researchers were monitoring changes to telomere length in white blood cells known as lymphocytes. For this new study, the researchers looked at how sudden stress affected a group of biological markers that included telomerase, an enzyme that rebuilds telomeres, because levels of the enzyme would react more quickly to stress than the length of telomeres themselves. Specifically, they compared how moderate and high doses of omega-3s and a placebo influenced those markers during and after an experimental stressor. Study participants took either 2.5 grams or 1.25 grams of omega-3s each day, or a placebo containing a mix of oils representing a typical American's daily intake. After four months on the supplements, the 138 research participants, age 40-85, took a 20-minute test combining a speech and a math subtraction task that is known to reliably produce an inflammatory stress response. Only the highest dose of omega-3s helped suppress damage during the stressful event when compared to the placebo group, lowering cortisol and a pro-inflammatory protein by an average of 19% and 33%, respectively. Results from blood samples showed that both doses of omega-3s prevented any changes in telomerase levels or a protein that reduces inflammation in the two hours after participants experienced the acute stress, meaning any needed stress-related cell repair—including telomere restoration—could be performed as usual. In the placebo group, those repair mechanisms lost ground: Telomerase dropped by an average of 24% and the anti-inflammatory protein decreased by an average of at least 20%. "You could consider an increase in cortisol and inflammation potential factors that would erode telomere length," Madison said. "The assumption based on past work is that telomerase can help rebuild telomere length, and you want to have enough telomerase present to compensate for any stress-related damage. "The fact that our results were dose-dependent, and we're seeing more impact with the higher omega-3 dose, would suggest that this supports a causal relationship." The researchers also suggested that by lowering stress-related inflammation, omega-3s may help disrupt the connection between repeated stress and depressive symptoms. Previous research has suggested that people with a higher inflammatory reaction to a stressor in the lab may develop more depressive symptoms over time. "Not everyone who is depressed has heightened inflammation—about a third do. This helps explain why omega-3 supplementation doesn't always result in reduced depressive symptoms," Kiecolt-Glaser said. "If you don't have heightened inflammation, then omega-3s may not be particularly helpful. But for people with depression who do, our results suggest omega-3s would be more useful." The 2.5-gram dose of omega-3s is much higher than what most Americans consume on a daily basis, but study participants showed no signs of having problems with the supplements, Madison said.           Want to be robust at 40-plus? Meeting minimum exercise guidelines won't cut it 5 hours of moderate activity a week may be required to avoid midlife hypertension, UCSF-led study shows University of California at San Francisco, April 15, 2021 Young adults must step up their exercise routines to reduce their chances of developing high blood pressure or hypertension - a condition that may lead to heart attack and stroke, as well as dementia in later life. Current guidelines indicate that adults should have a minimum of two-and-a-half hours of moderate intensity exercise each week, but a new study led by UCSF Benioff Children's Hospitals reveals that boosting exercise to as much as five hours a week may protect against hypertension in midlife - particularly if it is sustained in one's thirties, forties and fifties.  In the study publishing in American Journal of Preventive Medicine on April 15, researchers followed approximately 5,000 adults ages 18 to 30 for 30 years. The participants were asked about their exercise habits, medical history, smoking status and alcohol use. Blood pressure and weight were monitored, together with cholesterol and triglycerides.  Hypertension was noted if blood pressure was 130 over 80 mmHg, the threshold established in 2017 by the American College of Cardiology/American Heart Association.  The 5,115 participants had been enrolled by the Coronary Artery Risk Development in Young Adults (CARDIA) study and came from urban sites in Birmingham, Ala., Chicago, Minneapolis and Oakland, Calif. Approximately half the participants were Black (51.6 percent) and the remainder were White. Just under half (45.5 percent) were men.  Fitness Levels Fall Fast for Black Men Leading to More Hypertension Among the four groups, who were categorized by race and gender, Black men were found to be the most active in early adulthood, exercising slightly more than White men and significantly more than Black women and White women. But by the time Black men reached age 60, exercise intake had slumped from a peak of approximately 560 exercise units to around 300 units, the equivalent to the minimum of two-and-a-half hours a week of moderate intensity exercise recommended by the U.S. Department of Health and Human Services. This was substantially less exercise than White men (approximately 430 units) and slightly more than White women (approximately 320 units). Of the four groups, Black women had the least exercise throughout the study period and saw declines over time to approximately 200 units. "Although Black male youth may have high engagement in sports, socio-economic factors, neighborhood environments, and work or family responsibilities may prevent continued engagement in physical activity through adulthood," said first author Jason Nagata, MD, of the UCSF Division of Adolescent and Young Adult Medicine. Additionally, Black men reported the highest rates of smoking, which may preclude physical activity over time, he noted. Physical activity for White men declined in their twenties and thirties and stabilized at around age 40. For White women, physical activity hovered around 380 exercise units, dipping in their thirties and remaining constant to age 60. Rates of hypertension mirrored this declining physical activity. Approximately 80-to-90 percent of Black men and women had hypertension by age 60, compared with just below 70 percent for White men and 50 percent for White women.  "Results from randomized controlled trials and observational studies have shown that exercise lowers blood pressure, suggesting that it may be important to focus on exercise as a way to lower blood pressure in all adults as they approach middle age," said senior author Kirsten Bibbins-Domingo, MD, PhD, of the UCSF Department of Epidemiology and Biostatistics.  "Teenagers and those in their early twenties may be physically active but these patterns change with age. Our study suggests that maintaining physical activity during young adulthood - at higher levels than previously recommended - may be particularly important." More Exercise from Youth to Midlife Offers Best Protection Against Hypertension When researchers looked at the 17.9 percent of participants who had moderate exercise for at least five hours a week during early adulthood - double the recommended minimum - they found that the likelihood of developing hypertension was 18 percent lower than for those who exercised less than five hours a week. The likelihood was even lower for the 11.7 percent of participants who maintained their exercise habits until age 60.  Patients should be asked about physical activity in the same way as they are routinely checked for blood pressure, glucose and lipid profiles, obesity and smoking, Nagata said, and intervention programs should be held at schools, colleges, churches, workplaces and community organizations. Black women have high rates of obesity and smoking, and low rates of physical activity, he said, and should be an important group for targeted intervention.  "Nearly half of our participants in young adulthood had suboptimal levels of physical activity, which was significantly associated with the onset of hypertension, indicating that we need to raise the minimum standard for physical activity," Nagata said. "This might be especially the case after high school when opportunities for physical activity diminish as young adults transition to college, the workforce and parenthood, and leisure time is eroded."     Study finds association between periodontal disease and low intake of minerals, vitamins and dietary fiber in young adult women Tokyo Medical and Dental University, April 12, 2021 According to news reporting out of Tokyo, Japan, research stated, “Dietary habits of middle-aged and elderly individuals affected by periodontal disease (PD) differ from those who are unaffected by it, according to previous reports. However, in young adults, there are only a few reports that show a correlation between nutrient/food intake and PD.” Our news journalists obtained a quote from the research from Tokyo Medical and Dental University (TMDU), “Moreover, no report till date has assessed the correlation between dietary habits and PD using a self-administered diet history questionnaire (DHQ). Therefore, we assessed this correlation using a DHQ in young adult women who are likely to develop PD. The participants were enrolled from 2 universities and included 120 female college students a mean age of 20.4 y. The participants were assessed for the presence of PD according to the community periodontal index and were divided into two groups, the PD group and the non-PD group. Their dietary habits were investigated using a DHQ and the level of difficulty in chewing food was assessed. The PD group had a significantly lower nutrient intake of minerals, fat-soluble vitamins, water-soluble vitamins, and dietary fiber than the non-PD group. In terms of food groups, the PD group consumed significantly lesser amounts of green and yellow vegetables (GYV) than the non-PD group. Multivariate analysis revealed that the PD group had significantly lower intakes of vitamin E and GYV than the non-PD group. The PD group consumed significantly lesser amounts of hard foods than the non-PD group.” According to the news editors, the research concluded: “Young adult women who were evaluated for PD by a screening test had a significantly lower nutrient/food intake than those without a PD.” This research has been peer-reviewed.       Just 2 days of increased sugar intake can harm your gut health, warn researchers University of Alberta, April 16, 2021 Researchers from the University of Alberta in Canada found that short-term increases in sugar intake can increase the risk of inflammatory bowel disease. Their finding, which was published in Scientific Reports, is a reminder that eating healthy must be sustained in order to keep your gut in good shape. “Surprisingly, our study shows that short-term sugar consumption can really have a detrimental impact, and so this idea that it’s OK to eat well all week and indulge in junk food on the weekend is flawed,” said Karen Madsen, one of the study researchers. Increased sugar intake is bad for the gut Previous studies have shown that diets can affect your susceptibility to disease. Western diets, for example, have been implicated in the development of inflammatory bowel disease. But it’s still unclear when a poor diet begins to take a toll on your health, much less how it does so. To investigate, the researchers placed adult mice on a chow diet or a high-sugar diet and treated them with dextran sodium sulfate to induce ulcerative colitis, one of the major forms of inflammatory bowel disease. Disease severity was assessed daily. After two days, the mice on the high-sugar diet were at great risk of developing colitis. Their immune response also weakened while their gut permeability increased, allowing more bacteria and toxins to enter their bloodstream. “We wanted to know how long it takes before a change in diet translates into an impact on health. In the case of sugar and colitis, it only took two days, which was really surprising to us. We didn’t think it would happen so quickly,” said Madsen. The researchers attributed these effects to sugar’s impact on the gut bacteria. Eating sugary foods decreases the amount of “good” gut bacteria that produce short-chain fatty acids, which are critical for a strong immune response. Meanwhile, sugar feeds “bad” bacteria that promote inflammation and weaken your immunity.  Fortunately, the researchers found that supplementing with short-chain fatty acids helped reduce the negative effects of a high-sugar diet. Having these supplements as an option will be great for people struggling to change their bad eating habits. “People want to eat what they want to eat, so short-chain fatty acids could possibly be used as supplements to help protect people against the detrimental effects of sugar on inflammatory bowel disease,” said Madsen.     Rose water is an antimicrobial and anti-inflammatory remedy for skin infections Teikyo University (Japan), April 15, 2021 Rosa damascena, commonly known as Damask rose, is one of the most important and medicinally useful members of the Rosaceae (rose) family. It is an ornamental plant widely used to make perfumes and is reported to have plenty of beneficial properties. According to multiple studies, Damask rose has anti-HIV, antibacterial, antioxidant, antitussive, hypnotic and antidiabetic properties. It has also shown relaxant effects on the tracheal chains of guinea pigs. In a recent study, researchers at Teikyo University in Japan investigated two biological properties of Damask rose, specifically it’s antimicrobial and anti-inflammatory properties. They tested rose water made from high-quality Damask rose petals on two microbial pathogens, namely, Candida albicans and methicillin-resistant Staphylococcus aureus (MRSA), which commonly cause skin infections. The researchers reported their findings in an article published in Biological and Pharmaceutical Bulletin. Damask rose water is a natural antibiotic and anti-inflammatory agent Damask rose is a multipurpose plant widely known for its culinary and medicinal applications, among other things. Edible parts of Damask rose are used in various cuisines, including its young shoots, petals, fruits, leaves and seeds. Damask rose petals are used to make jams and add flavor to beverages, baked goods and desserts. They are also used for cooking dishes. Rosewater, which can be sweetened to produce rose syrup, is a byproduct of rose oil production. It is usually obtained by steam distilling Damask rose petals and taking the hydrosol portion of the rose petal distillate.  In different parts of the world, rose water, rose oil and a decoction made of Damask rose roots are used in traditional medicine for the treatment of various ailments, such as abdominal and chest pain, digestive problems and inflammation, especially of the neck. In North America, Indian tribes use the decoction as a cough remedy for children. Rose oil is used to treat depression and reduce stress and tension. Inhaling the vapor produced by heating rose oil is also believed to be an effective remedy for allergies, headaches and migraine. Damask rose water, on the other hand, is traditionally used to treat skin conditions, such as erythema (skin redness), itchiness and swelling. To evaluate its antimicrobial and anti-inflammatory properties, the researchers tested Damask rose water against C. albicans and MRSA and assessed its effects on the function of neutrophils, which are white blood cells that serve as key regulators of inflammatory reactions. The researchers reported that Damask rose water (2.2. percent solution) inhibited the mycelial growth of C. albicans and reduced the viability of MRSA within an hour of treatment. Damask rose water (five to 15 percent) also suppressed the activation of neutrophils induced by treatment with lipopolysaccharide (LPS), a bacterial toxin; tumor necrosis factor-alpha (TNF-a), a cell-signaling protein produced by immune cells; and N-formyl-Met-Leu-Phe (fMLP), a macrophage activator. Additionally, Damask rose water reduced LPS- and TNF-a-induced cell surface expression of the adhesion-related molecule, cluster of differentiation 11b (CD11b), which is rapidly elevated by the activation of neutrophils. The amount of CD11b in neutrophils is said to correlate with their activation and inflammation. However, Damask rose water did not affect the migratory capacity of neutrophils (with or without a chemoattractant). Based on these findings, the researchers concluded that Damask rose water can reduce the pathogenicity of microbes and attenuate neutrophil stimulation, thus inhibiting skin inflammation caused by microbial infections.     Study shows how chronic stress may inhibit the body's cancer-fighting ability University of Western Ontario, April 15, 2021 New research from Western University has shown how psychological stress hinders the immune system's defenses against cancer. By investigating the effects of chronic stresson the immune system's "emergency responders," researchers at the Schulich School of Medicine & Dentistry found that a stress-induced hormone impairs the ability of these immune cells to carry out their cancer-fighting function. Led by Mansour Haeryfar, Ph.D., the research looked specifically at innate-like T cells, which when functioning properly enable the immune system to look for potentially cancerous cells in the body and destroy them. The study was published today in Cell Reports. Innate-like T cells include invariant natural killer T (iNKT) and mucosa-associated invariant T (MAIT) cells, which were the subjects of this investigation. iNKT cells are present in small numbers in many tissues but are especially enriched in the human omentum, an apron-like layer of fatty tissue. MAIT cells are present in relatively high numbers in the human peripheral blood, gut, lungs and liver among other organs. "These innate-like T cells are our immune system's emergency responders," said Haeryfar. "They react quickly to pathogens and cancer cells and are in a pre-activated mode, so they are like loaded guns, ready to respond." Previous studies have shown that when a person experiences chronic psychological and emotional stress, the body's immune system is suppressed, dampening its ability to fight cancer and opportunistic infections. This happens in large part because stress hormones kill off some of the body's immune cells. However, Haeryfar and his team showed that innate-like T cells actually don't die as a result of chronic stress but their cancer-fighting abilities are drastically impaired by stress-induced hormones called glucocorticoids. This impairment led to a striking increase in cancer metastasis in a mouse model. "We found that innate-like T cells survive when the host is under stress, but their functions are compromised," Haeryfar said. "The cells cannot make enough of their beneficial mediators to help fight cancer, so the metastatic burden is increased because of the stress." The team also looked at the effects of natural and synthetic glucocorticoids on innate-like T cells in human blood and liver tissue, where they are abundant. This was important to providing initial evidence that some of the discoveries made in the mouse models were valid for human cells as well, said Patrick Rudak, Ph.D. Candidate in Haeryfar's lab. One of the important implications of this work is that innate-like T cells are currently being investigated for cancer immunotherapy treatment. This study demonstrates that their therapeutic potential can be dampened by psychological stress, said Haeryfar, and this finding needs to be considered when designing or administering those therapies. Rudak added: "Our study demonstrates that, despite being capable of instigating robust anti-tumor immune responses under normal conditions, innate-like T cells completely fail to protect against tumors during psychological stress." Because the study also uncovered the mechanisms by which stress diminishes T cell function, the researchers hope they can use the information to help design immunotherapies involving these cells that will still be effective in psychologically stressed patients.

David Bernstein, Elisabeth Bloxam & Caroline Mirkes were all recent Fulbright alumnae to / from Luxembourg. They share their transformative experiences. If you go through the who's who of Luxembourg's heavy-hitters and glitterati, there will be a number who were Fulbright Scholars to America. This cultural and educational scholarship offers strong candidates an outstanding opportunity to live and study in America at any point in life after a Bachelor's degree. And it's not just for Luxembourg passport holders (although your statistical chances of getting a place with one may be higher); the Fulbright programme operates between 160 countries. Fulbrighters talk of the life-long relationships they build both personally and professionally in this evermore interconnected world. You will hear in this conversation the ‘high value return on investment', as David likes to put it, and believes it might be the greatest form of local citizen diplomacy. My guests Elisabeth Bloxam, herself a Fulbright alumna, is the Director of Programs at the Commission for Educational Exchange between the United States, Belgium and Luxembourg, the Fulbright Commission in Brussels - your go-to person if you're interested in this scholarship. Elisabeth spent her Fulbright year in Luxembourg as an English Teaching Assistant, and has been with the Fulbright Commission in Brussels since 2016. Prior to that she studied European Studies and French & Francophone Studies from the College of William & Mary in Virginia (2015). David Berstein was a Fulbright Research Awardee in 2013 in Luxembourg, when he studied towards a Master in Entrepreneurship and Innovation from the University of Luxembourg. He also spent time working with Silicon Luxembourg and the US Embassy during that academic year, and harbours a hope to return as US Ambassador to Luxembourg one day! David has an MD and MBA from the University of Rochester School of Medicine & Dentistry and Simon Business School. He spent a year at the Institute For Strategy & Competitiveness at Harvard Business School. Currently, David is a PhD student at the University of Leiden in The Netherlands and an orthopaedic surgery resident physician at the Harvard Combined Orthopaedic Residency Program (HCORP), providing musculoskeletal care to patients at Massachusetts General Hospital, Brigham & Women's Hospital, Beth Israel Deaconess Medical Center, and Boston Children's Hospital. David is passionate about “fixing” America's healthcare system. Caroline Mirkes is a composer, actress, cellist and pianist from Luxembourg. The Fulbright programme took her to New York University for a Masters, but she also became a part-time student at the Lee Strasberg Institute where she began to study acting. Prior to that, Caroline studied Cello Performance at Maastricht Conservatorium, the Koninklijk Conservatorium of Brussels and Escola Superior de Barcelona. Now based in Vienna, Caroline continues to create global projects and concerts, which include Performers.lu, Cello Octet Luxembourg and art creations. Recently, her short film Criminal Eyes is selected for the Lee Strasberg Film Festival in NYC and nominated for Best Supporting Actress. She continues acting at the Schauspiel schule Wien. And aside from that, finds time for dance, acrobatics and aerial silk lessons! Origins of the Fulbright Program Just after the Second World War in September 1945, a freshman senator from Arkansas, J. William Fulbright, introduced a bill in the U.S. Congress that called for the use of proceeds from the sales of surplus war property to fund the “promotion of international good will through the exchange of students in the fields of education, culture and science.” One year later, President Harry S. Truman signed the Fulbright Act into law. Senator Fulbright saw an opportunity for good in the wake of the Second World War and proposed a program whose aim was to create the kind of mutual understanding and people-to-people relationships that would prevent such global conflict from happening again. The Fulbright Program has blossomed to become the flagship international educational exchange program of the U.S. Department of State. International educational and cultural exchange In Luxembourg, the Fulbright Program provides scholarships for Luxembourgish citizens who wish to conduct research or pursue graduate study in the USA and for American citizens to come study and teach in Luxembourg. The Fulbright Commission in Brussels administers the Fulbright Program for citizens of Belgium and Luxembourg as well as participants in the Fulbright Schuman Program, but the program operates in over 160 countries worldwide and awards approximately 8,000 grants annually. Roughly 1,900 U.S. students, 4,000 foreign students, 1,200 U.S. scholars, and 900 visiting scholars receive awards, in addition to several hundred teachers and professionals. Information about grants for Belgian and Luxembourgish citizens, educational and cultural exchanges offered by the U.S. Embassy to Luxembourg can be found via my article on RTL Today. https://www.fulbright.be/awards/grants-for-belgian-and-luxembourgish-citizens/ https://lu.usembassy.gov/education-culture/

Dr. Ashley Stein is a Board Certified Naturopathic Medical Doctor (NMD) in Arizona. She received her Bachelor of Science in Biomedical Engineering at Boston University, but quickly learned that medicine is much more than surgeries and pharmaceuticals. Growing up loving both nature and medicine, she went on to attended medical school in Arizona where she earned her Doctorate of Naturopathic Medicine at SCNM. Dr. Stein loves to treat the whole person and strives to find the root cause of every patient’s condition. She incorporates evidence-based medicine with ancient wisdom to provide an individualized health plan, helping you not only get well, but also provide the right tools to continue to thrive and optimize your longevity. Join the community on Dentaltown at https://www.dentaltown.com

This episode we welcome on Shaily, our representative from Schulich School of Medicine & Dentistry at Western University! Shaily takes us through the admissions process, curriculum, and student life of Schulich School of Medicine. Thanks for joining us Shaily!

Dr. Steven Flanagan is Howard A. Rusk Professor of Rehabilitation Medicine and Chairperson of the Department of Rehabilitation Medicine at NYU Langone Health. He joined NYU Langone Medical Center in 2008 as Professor and Chairman of Rehabilitation Medicine and Medical Director of Rusk Rehabilitation after serving as Vice Chairman of Rehabilitation Medicine at Mount Sinai School of Medicine. He serves on numerous medical advisory boards and is a peer reviewer for several scientific journals. He has authored numerous chapters and peer-reviewed publications, and has participated in both federally- and industry-sponsored research. His medical degree is from the University of Medicine & Dentistry of New Jersey and he completed his residency at Mt. Sinai Medical Center/Cabrini, Rehabilitation Medicine. PART 1 In Part 1 of his presentation, Dr. Flanagan discussed the value that physical medicine and rehabilitation (PM&R) add to health care.His objective in this session is to give an overview of health care reform and its impact on PM&R. Many changes have occurred since he began practicing medicine three decades ago. Health care reform is real. From 1960 to 2010, wages and GDP increased, but nowhere close to the enormous rise in health care expenditures, which are not sustainable. Also, we no longer can claim that we have the best health outcomes compared to other nations. Recognizing that health spending could no longer continue at such a rapid pace, the government came up with something called the Sustainable Growth Rate (SGR) to limit the outlandish expansion of health care costs. The attempt never achieved what was intended and Congress terminated the SGR in 2015. It was replaced by MACRA, the Medicare Access and CHIP Reauthorization Act of 2015, which redefined how physicians would be reimbursed and it is based on quality measures that they would have to meet. The objective is to achieve the triple aim of health care reform: improve health care quality, produce better outcomes, and improve the patient experience. A quadruple aim includes improving the satisfaction of providers. He indicated that management of post-acute care is of importance and that PM&R is uniquely situated to be involved in achieving the triple aim.  It can do so by focusing on patient-centered coordinated care that is comprehensive across the entire continuum. PART 2  Listeners to Part 1 of Dr. Flanagan’s presentation may recall that he discussed health reform efforts to control health care costs and how the provision of physical medicine and rehabilitation (PM&R) services has a unique role to play in achieving health reform’s triple aim. In Part 2, his comments had a focus on intensive care unit patients, a group associated with large health care costs and one not usually associated with the provision of rehabilitation services. What about safety? It’s feasible, but is it wise? Should we get folks up and walking who are so critically ill? Aren’t we putting them at risk of all sorts of bad things from happening? It is safe and the outcomes are fine and there is research to prove it. We are enhancing mobility, decreasing the number of days patients are on ventilators, and in some cases, not only are we not causing worse mortality, we are decreasing mortality. If you are doing all of this, the last question is what about costs? Despite increasing the use of PT, OT, and Speech staff, by getting patients out of the hospital faster, there is a cost savings. A pilot study was done at NYU to look at what happens to patients after they left the hospital to see if there were any additional savings. The results show that it was possible to reduce hospitalization, reduce the average direct cost per day, and there was a significant increase in the proportion of patients who were discharged to the community with no services at all. The latter outcome represented an overall cost savings for the health system. He also provided information about something that is relatively new and what they are working on at NYU, which is site neutral payments. A question and answer period followed his presentation.

For this special series we’re partnering with the Association of Family Health Teams of Ontario (AFHTO) to highlight the work of several amazing primary healthcare teams. Family health teams provide comprehensive primary care and are based on a collaborative model where physicians, nurse practitioners, nurses, dieticians, social workers and many more disciplines work together. In this episode we speak with Janet Dang, Transformation Lead for Primary Care at the Thames Valley Family Health Team, part of the London Middlesex Primary Care Alliance, and Asher Frydman, a 2nd year medical student at the Schulich School of Medicine & Dentistry at Western University. Asher was one of the early volunteers to join Janet’s Covid project. In the early stages of Covid-19, Janet and her team realized the area was experiencing a severe shortage of PPE. With the help of student volunteers and donations from businesses and the community, this grassroots effort grew to become the primary PPE distribution hub for the provincial supply within the region. Quotables “I saw that there was a small project that was at its grassroots stage, collecting PPE from the community and I said this is absolutely I want to do.” – AF “We started to call a couple of places and more PPE came in and things were being picked up, and it started to snowball. We thought, oh no, there’s only the three of us. We can’t really do this for the entire city!” – JA   “The actual cycle of making sure you’re tracking all of it, making sure they’re getting the exact amounts they need – no more no less – that really took a lot of cycles, discussing with each other and individuals who work higher up like Janet as well as some other doctors, to make sure we were working efficiently as well as ethically.” – AF   “The (AFHTO) conference gave us a chance to explain there are hub systems that can really work, and that can actually make a difference in your communities, that can maintain close relationships with physicians and other primary care providers to ensure they can continue their operations during a pandemic such as Covid.” – AF   “It was incredible to see how both the community can step up to help healthcare workers and how future healthcare workers are willing to step up as well to make sure we have that continuity of care.” – AF   “It just shows that when we communicate and work together in a way to provide support in a time of need, it just was truly grassroots and so organic, it was something very special to be a part of.” – JA   Mentioned in this Episode: AFHTO Association of Family Health Teams of Ontario Thames Valley Family Health Team Schulich School of Medicine & Dentistry SoleScience Fanshawe College   Access More Interviews with Healthcare Leaders at HIROC.com/podcast Follow us on Twitter, and listen on iTunes. Email us at Communications@HIROC.com.

Dr. Steven Flanagan is Howard A. Rusk Professor of Rehabilitation Medicine and Chairperson of the Department of Rehabilitation Medicine at NYU Langone Health. He joined NYU Langone Medical Center in 2008 as Professor and Chairman of Rehabilitation Medicine and Medical Director of Rusk Rehabilitation after serving as Vice Chairman of Rehabilitation Medicine at Mount Sinai School of Medicine. He serves on numerous medical advisory boards and is a peer reviewer for several scientific journals. He has authored numerous chapters and peer-reviewed publications, and has participated in both federally- and industry-sponsored research. His medical degree is from the University of Medicine & Dentistry of New Jersey and he completed his residency at Mt. Sinai Medical Center/Cabrini, Rehabilitation Medicine. PART 1 In Part 1 of his presentation, Dr. Flanagan discussed the value that physical medicine and rehabilitation (PM&R) add to health care.His objective in this session is to give an overview of health care reform and its impact on PM&R. Many changes have occurred since he began practicing medicine three decades ago. Health care reform is real. From 1960 to 2010, wages and GDP increased, but nowhere close to the enormous rise in health care expenditures, which are not sustainable. Also, we no longer can claim that we have the best health outcomes compared to other nations. Recognizing that health spending could no longer continue at such a rapid pace, the government came up with something called the Sustainable Growth Rate (SGR) to limit the outlandish expansion of health care costs. The attempt never achieved what was intended and Congress terminated the SGR in 2015. It was replaced by MACRA, the Medicare Access and CHIP Reauthorization Act of 2015, which redefined how physicians would be reimbursed and it is based on quality measures that they would have to meet. The objective is to achieve the triple aim of health care reform: improve health care quality, produce better outcomes, and improve the patient experience. A quadruple aim includes improving the satisfaction of providers. He indicated that management of post-acute care is of importance and that PM&R is uniquely situated to be involved in achieving the triple aim.  It can do so by focusing on patient-centered coordinated care that is comprehensive across the entire continuum. PART 2  Listeners to Part 1 of Dr. Flanagan’s presentation may recall that he discussed health reform efforts to control health care costs and how the provision of physical medicine and rehabilitation (PM&R) services has a unique role to play in achieving health reform’s triple aim. In Part 2, his comments had a focus on intensive care unit patients, a group associated with large health care costs and one not usually associated with the provision of rehabilitation services. What about safety? It’s feasible, but is it wise? Should we get folks up and walking who are so critically ill? Aren’t we putting them at risk of all sorts of bad things from happening? It is safe and the outcomes are fine and there is research to prove it. We are enhancing mobility, decreasing the number of days patients are on ventilators, and in some cases, not only are we not causing worse mortality, we are decreasing mortality. If you are doing all of this, the last question is what about costs? Despite increasing the use of PT, OT, and Speech staff, by getting patients out of the hospital faster, there is a cost savings. A pilot study was done at NYU to look at what happens to patients after they left the hospital to see if there were any additional savings. The results show that it was possible to reduce hospitalization, reduce the average direct cost per day, and there was a significant increase in the proportion of patients who were discharged to the community with no services at all. The latter outcome represented an overall cost savings for the health system. He also provided information about something that is relatively new and what they are working on at NYU, which is site neutral payments. A question and answer period followed his presentation.

Libby Znaimer is joined by Dr. Shaf Keshavjee, director of the Toronto Lung Transplant Program and surgeon-in-chief at the University Health Network (UHN) and Dr. Janet Martin, an associate professor at the Schulich School of Medicine & Dentistry at Western University. She has been involved with a global team of researchers looking into the long-term impact of the pandemic on surgeries. A new study by the Canadian Medical Association Journal (CMAJ) indicates that it could take longer than a year and a half to get through the backlog of surgeries in Ontario as a result of the pandemic. Libby and our panel of medical experts weigh in on the study's findings and we hear from listeners who are being directly impacted by this reality of our healthcare system. Listen live, weekdays from noon to 1, on Zoomer Radio!

We are super grateful this week to be joined by Wendy, an MD/PhD candidate at Schulich School of Medicine & Dentistry! Wendy walks us through her experiences as a premed and what is required of you to be considered a competitive candidate for the MD/PhD dual degree. We discuss the admission process, the expectations with regards to research, future career directions, and much more. Thanks to Wendy for joining us and thanks to our listeners for tuning in for another week of Pluripotent Premed!

Welcome back to Multipotent MD! This week, we're joined by Dr. John Yoo from the Department of Otolaryngology, Head and Neck Surgery, as well as the new Dean of Schulich School of Medicine & Dentistry! We had the opportunity to dive into Dr. Yoo's career in medicine, as we discuss his journey through Otolaryngology and Surgical Oncology/Facial Reconstruction. We talk about the scope of his work, and how he divides his roles between his Facial Nerve Clinic and his Oncology practice. We then dive into his fascinating clinical research, where he discusses various innovative surgical techniques he's popularized, that are used all over the world. We then dive into the vast number of leadership roles that Dr. Yoo has held over the years. Finally, we congratulate Dr. Yoo on his new role as Dean of Schulich School of Medicine & Dentistry, and talk about his hopes and goals for his upcoming tenure. He graciously thanks the students for their adaptability and perseverance during these challenging times, and signs off with some inspiring advice! All of this and more on Multipotent MD!

This week on The Official OSAP Podcast Michelle Lee is Joined by Dr. Paul Feurstein. Dr. Feuerstein has been practicing dentistry for over 45 years. He studied chemistry, engineering, computer science, and music at the State University of New York, Stony Brook before earning his DMD at the University of New Jersey School of Medicine & Dentistry. Throughout his career, Dr. Feuerstein has been as fascinated with the advancement of dental technologies as he is with patient care. For over 30 years he has brought high tech advances into the office for patient care as well as to the entire dental industry as an expert teacher and consultant on dental technologies. He is currently the Technology Editor of Dentistry Today, the industry's leading trade journal, author of several articles about dental technology, and a lecturer at many national and local dental meetings. He is also an Adjunct Assistant Professor in General Dentistry at Tufts University. In 2010, Dr. Feuerstein was named “Clinician of the Year” at the Yankee Dental Congress. Episode Highlights Dr. Feurstein's Background Steps Dr. Feurstein takes before implementing a technology into his office  COVID-19    Quotes   “ I could speak both languages”   “ Ever since 1999 I have written one column every single month”    “Some of these so called opinion leaders are giving their opinions without any basis”   “You have to be savvy… and read the specs”    “When the crown comes in.. it fits, it just fits”    “The one thing that hasn't changes is relationships, being nice to your patients”    “Relationships are critical in a dental practice”  Links OSAP's homepage: https://www.osap.org/ Michelle Lee's email:   mlee@osap.org The Dental Podcast Network Channel One homepage: http://dentalpodcastnetworkchannelone.otcpn.libsynpro.com/

Welcome to PsychEd, the psychiatry podcast for medical learners, by medical learners. This episode covers medical trainee wellness during the COVID-19 pandemic with expert guest Dr. Deanna Chaukos, Staff Psychiatrist at Mount Sinai Hospital in Toronto and Wellness Lead for the Psychiatry Residency program at the University of Toronto.    The learning objectives for this episode are as follows:   By the end of this episode, you should be able to… Define wellness and burnout and their importance in medical education/psychiatry Understand strategies on how to maintain our own wellness and prevent burnout Understand strategies to help others maintain their wellness and deal with burnout *All through the lens of the COVID-19 pandemic   Hosts: Dr. Alex Raben (PGY5), Gray Meckling (CC3), Shaoyuan (Randi) Wang (CC3), Weam Sieffien (CC3)   Guest Staff Psychiatrist: Dr. Deanna Chaukos (Sinai Health Systems, Toronto)   Resources COVID-19 Resources for Residents, infographic prepared by residents at the University of Toronto, including team member of PsychEd Nikhita Singhal Resources for MD Wellness Improving Mental Health During COVID-19 University of Toronto Office of Health Professions Student Affairs OHPSA University of Toronto Postgraduate Wellness Office at UofT Gerstein Crisis Centre CAMH: COVID-19 Information for Healthcare Workers CAMH self-referral for healthcare workers to access mental health services UofT Faculty of Medicine: COVID-19 Wellness Resources for Faculty and Trainees Canadian Psychiatric Association - COVID-19 American Psychiatric Association Well-being Resources Seven tips for staying grounded as the world grapples with COVID-19: UofT Expert AMA: 6 ways to address physician stress during COVID-19 pandemic UBC - COVID-19 Resident Wellness Resources Youtube video: Three steps to coping with anything (including COVID-19) MHCC: Resource Hub: Mental health and wellness during the COVID-19 pandemic CMHA: COVID-19 and mental health   Articles CMA: Maintaining Your and Your Family’s Well-being During a Pandemic BMJ Opinion: COVID-19 - the impact on our medical students will be far-reaching AAMC: “A terrifying privilege”: Residency during the COVID-19 Outbreak AMA: Residency in a pandemic: How COVID-19 is affecting trainees CMAJ: Medical education needs reform to improve student well-being and reduce burnout, say experts   Examples of Medical Student Initiatives UofT News: As COVID-19 battle escalates, U of T students offer busy health-care workers help on the home front UofT News: Medical students collect personal protective gear for front line health-care workers, donate through U of T UofT News: 'We care and are here for them': U of T students help seniors cope with distancing during COVID-19 COVID-19 Central Making a difference: UBC students help frontline medical workers during COVID-19 McGill students rally their peers to provide support to frontline workers U of A medical students offering emergency child care to physicians and front-line health workers UCalgary medical and nursing students quickly answer the call for COVID-19 help News: Medical students providing support during COVID-19 containment effort (Schulich School of Medicine & Dentistry, Western University) Queen's students volunteer to help Kingston's medical professionals UOttawa MD students pitch in to help frontline health workers during COVID-19 McMaster med students help their future colleagues during COVID-19   References  Brooks, S. K., Webster, R. K., Smith, L. E., Woodland, L., Wessely, S., Greenberg, N., & Rubin, G. J. (2020). The psychological impact of quarantine and how to reduce it: rapid review of the evidence. The Lancet. Eckleberry-Hunt, J., Van Dyke, A., Lick, D., & Tucciarone, J. (2009). Changing the conversation from burnout to wellness: physician well-being in residency training programs. Journal of Graduate Medical Education, 1(2), 225-230. Eckleberry-Hunt, J., Lick, D., Boura, J., Hunt, R., Balasubramaniam, M., Mulhem, E., & Fisher, C. (2009). An exploratory study of resident burnout and wellness. Academic Medicine, 84(2), 269-277. Dewey, C., Hingle, S., Goelz, E., & Linzer, M. (2020). Supporting clinicians during the COVID-19 pandemic. Annals of Internal Medicine. Drolet, B. C., & Rodgers, S. (2010). A comprehensive medical student wellness program—design and implementation at Vanderbilt School of Medicine. Academic Medicine, 85(1), 103-110. Dyrbye, L. N., Burke, S. E., Hardeman, R. R., Herrin, J., Wittlin, N. M., Yeazel, M., ... & Satele, D. V. (2018). Association of clinical specialty with symptoms of burnout and career choice regret among US resident physicians. Jama, 320(11), 1114-1130. Kealy, D., Halli, P., Ogrodniczuk, J. S., & Hadjipavlou, G. (2016). Burnout among Canadian psychiatry residents: a national survey. The Canadian Journal of Psychiatry, 61(11), 732-736. Lai, J., Ma, S., Wang, Y., Cai, Z., Hu, J., Wei, N., ... & Tan, H. (2020). Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019. JAMA network open, 3(3), e203976-e203976. Lebensohn, P., Dodds, S., Benn, R., Brooks, A. J., & Birch, M. (2013). Resident wellness behaviors. Fam. Med, 45, 541-549. Santarone, K., McKenney, M., & Elkbuli, A. (2020). Preserving mental health and resilience in frontline healthcare workers during COVID-19. The American Journal of Emergency Medicine. Shiralkar, M. T., Harris, T. B., Eddins-Folensbee, F. F., & Coverdale, J. H. (2013). A systematic review of stress-management programs for medical students. Academic Psychiatry, 37(3), 158-164. CPA Note: The views expressed in this podcast do not necessarily reflect those of the Canadian Psychiatric Association.   For more PsychEd, follow us on Twitter (@psychedpodcast), Facebook (PsychEd Podcast), and Instagram (@psyched.podcast). You can provide feedback by email at psychedpodcast@gmail.com. For more information visit our website at psychedpodcast.org.

Thank you for joining us on the most important episode we've published to date, and perhaps will be the most important episode we will publish - for more reasons than we could possibly articulate here in written text. In this episode, we discuss the inescapably difficult but exceedingly important matter of quality versus quantity life - when given a terminal diagnosis. It is impossible to convey our saddened we are that a dear friend to this show, Dr. Karen Rees-Milton (who joined us on episode 27), is bravely surviving a terminal diagnosis. As a true reflection of her character, commitment, and passion for life, Karen wishes to broach with us just how important it is for communication between doctors and patients about the end of life. We are also so grateful to be joined by Dr. Sarah McLean, an Assistant Professor of Physiology & Pharmacology and Anatomy & Cell Biology at Western University's Schulich School of Medicine & Dentistry. Like Karen, Sarah is an expert in cancer research - and she too has directly experienced the pains of being a centre for communication for and between her brothers, doctors, and her dear father, who she lost very quickly to cancer in the summer of 2019. Karen and Sarah are experts in cancer research, and their direct experiences with cancer make for a particularly important conversation. As you will see, doctors do not always communicate quickly or efficiently about terminal diagnoses. The very human impulse to make people happy in desperate situations often creates moral ambiguity that distracts from the hard but important conversation about whether or not often debilitating treatments are worth one's precious time. We hope that you will use this episode as a guide to help you when faced with these difficult matters, as we all will inevitably deal with them - one way, or another.    As mentioned in the episode, please visit the London Regional Cancer Program, the Zane Cohen Centre for Digestive Diseases, Kingston General Hospital's Endoscopy Unit, and Jayne Dill's (RN) New Before You Go - a wonderful woman and tremendous resource for helping us navigate matters of value, wishes, and communication when dealing with the end of life.   Follow your hosts: @Derekcrim | @whatsthatdata | @wtncast Dr. Sarah McLean can be followed on Twitter @drsarahmclean Email us Subscribe for updates   Follow us on Apple Music and Spotify 

Howard travels to the Tel Aviv University School of Dental Medicine to discuss dental education and dentistry in general with Professor Shlomo Matalon, the school's Director of Dental Clinics.

Dr. Uma Dhanabalan is Founder/CEO, Global Health & Hygiene Solutions LLC, Uplifting Health & Wellness, Natick, MA. "She is a highly respected physician trained in Family Medicine, Occupational & Environmental Medicine, specialized in heavy metals, a Fellow of the American Academy of Family Physicians, a Cannabinoid Medicine Specialist and Medical Review Officer. She completed her Bachelor of Arts degree with high honors from Rutgers University and a Medical degree from the University of Medicine & Dentistry in Newark, New Jersey. She completed a Family Practice Residency at the Medical University of South Carolina, in Charleston, South Carolina and then her Master’s in Public Health and Occupational & Environmental Medicine Residency and Fellowship at the Harvard School of Public Health in Boston Massachusetts. She is also certified by the American Academy of Cannabinoid Medicine and by the Medical Review Officer Certification Council. She has received awards from the American College of Occupational & Environmental Medicine for her research project: “Occupational & Environmental Exposure to Lead in South India”, from The 7th World Ayurveda Conference & Arogya Expo for her presentation “Cannabis & The Therapeutic Uses” and the Educational Achievement Award presented by Clover Leaf at Cannabis Business Award 2017 She is the Founder/CEO for Global Health & Hygiene Solutions, LLC established in 2006, with a mission to promote wellness and prevent illness. She worked for Kimberly Clark as Regional Medical Director for Asia Pacific She worked for the Hanford Site in Richland, Washington, the largest and most complex cleanup projects in the world, where plutonium was manufactured for the first nuclear bomb detonated in Japan. She created the TotalHealthCareTHC model where she “Educates Embraces Empowers” patients and promotes cannabis as a treatment option at Uplifting Health and Wellness, in Natick, Massachusetts. She is an advocate, activist, and educator and speaks globally about cannabis as a plant medicine. Her mission is to change the Stigma regarding Cannabis and for the world to know about the Endocannabinoid system through education" https://necann.com/news/speaker/dr-uma-dhanabalan/ Dr. Dhanabalan states: “Cannabis is not for everyone, yet it should be a first-line option not the last resort,” and “Cannabis is not an entrance drug, it is an exit drug from pharmaceuticals narcotics and alcohol.” Meeting and talking to Dr. Uma was a transformational experience for me. She logically explains the evolution of her understanding of cannabinoid medicine, starting from an early age. Born in India, moving to the US from India at age 8 with her father, a chemical engineer and her mother, a mathematician and working in computer software, she was raised with a strong interest in science as well as a passion for understanding preventative health. "I'm a family doctor, went to South Carolina (and) finished my practice residency, then I decided to do my second life which brought me back to Massachusetts to Harvard. Where I did my masters in public health because that's where I really realized I had to go back to that calling of preventative medicine." She goes on to say, " That was something that has been rooted in me, that's never really encouraged in most doctors' lives. You know, it's always -make a diagnosis- what's the treatment plan? What's the ICD code that you have to bill with, and how many people?... La la la la la. That's the world of healthcare. Ultimately, what people have to live with today. I was very fortunate also, not only did I have all of that as a background, I had a culture. My parents kept up with my language. I spoke five different languages when I came to this country." Dr. Uma discusses various experiences she had leading up to her "AHA" moment when she was with her mother who was dying of lung cancer for unbeknownst reasons, "she had seen a TV program and I could still hear her saying using ganja and I damn well knew what that word was. I beelined it and I heard her said they're using it for COPD, asthma, lung cancer, PTSD, and I still remember that" From there Dr. Uma has gone on to become one of only 50 physicians certified to practice cannabinoid medicine in the United States. She was one of High Times' top 50 females in Cannabis in 2019. I'll share one more quote to wrap up this intro, with the 3 key facts she shares when doing public speaking, and often she is told by doctors that they just didn't know this; "number one, nobody, and I use the word nobody because there are no deaths ever in the world from this medicine. You cannot die from it. You may feel like you're dying, you ain't gonna die from it. Fact number two, the government has a patent number 66 35 07, issued on October 7, 2003, and it's owned by the government. And it clearly states cannabinoids, not just one, cannabinoids, as an antioxidant. And guess what? A neuroprotectant. There's nothing here about the developing brain. There's nothing here about neurotoxicity. It says neuroprotectant, and they have known about it for Parkinson's, Alzheimer's, dementia, strokes, protection of the heart. They have known about it. Fact number three, doctors had the liberty to write prescriptions because it was allowed. And it was in the United States pharmacopeia from 1852 to 1942." Wow. Check out her website to learn more: http://totalhealthcarethc.com/ Dr. Uma's Links: Facebook: https://www.facebook.com/profile.php?id=100008556311630 Twitter: https://twitter.com/drumasays Instagram: https://www.instagram.com/dr.uma_thc/ LinkedIn: https://www.linkedin.com/in/dr-uma-dhanabalan-md-mph-faafp-mro-cms-02843040/ Other links: https://necann.com/news/speaker/dr-uma-dhanabalan/ https://hightimes.com/news/honorees-high-times-female-50/ https://www.cancerschmancer.org/summit/ https://www.linkedin.com/pulse/cannabinoid-medicine-rebirth-nature-dr-uma-dr-david-bearman/

Dr. Uma Dhanabalan is Founder/CEO, Global Health & Hygiene Solutions LLC, Uplifting Health & Wellness, Natick, MA. "She is a highly respected physician trained in Family Medicine, Occupational & Environmental Medicine, specialized in heavy metals, a Fellow of the American Academy of Family Physicians, a Cannabinoid Medicine Specialist and Medical Review Officer.She completed her Bachelor of Arts degree with high honors from Rutgers University and a Medical degree from the University of Medicine & Dentistry in Newark, New Jersey. She completed a Family Practice Residency at the Medical University of South Carolina, in Charleston, South Carolina and then her Master’s in Public Health and Occupational & Environmental Medicine Residency and Fellowship at the Harvard School of Public Health in Boston Massachusetts. She is also certified by the American Academy of Cannabinoid Medicine and by the Medical Review Officer Certification Council.She has received awards from the American College of Occupational & Environmental Medicine for her research project: “Occupational & Environmental Exposure to Lead in South India”, from The 7th World Ayurveda Conference & Arogya Expo for her presentation “Cannabis & The Therapeutic Uses” and the Educational Achievement Award presented by Clover Leaf at Cannabis Business Award 2017She is the Founder/CEO for Global Health & Hygiene Solutions, LLC established in 2006, with a mission to promote wellness and prevent illness. She worked for Kimberly Clark as Regional Medical Director for Asia Pacific She worked for the Hanford Site in Richland, Washington, the largest and most complex cleanup projects in the world, where plutonium was manufactured for the first nuclear bomb detonated in Japan.She created the TotalHealthCareTHC model where she “Educates Embraces Empowers” patients and promotes cannabis as a treatment option at Uplifting Health and Wellness, in Natick, Massachusetts. She is an advocate, activist, and educator and speaks globally about cannabis as a plant medicine. Her mission is to change the Stigma regarding Cannabis and for the world to know about the Endocannabinoid system through education" https://necann.com/news/speaker/dr-uma-dhanabalan/Dr. Dhanabalan states: “Cannabis is not for everyone, yet it should be a first-line option not the last resort,” and “Cannabis is not an entrance drug, it is an exit drug from pharmaceuticals narcotics and alcohol.”Meeting and talking to Dr. Uma was a transformational experience for me. She logically explains the evolution of her understanding of cannabinoid medicine, starting from an early age. Born in India, moving to the US from India at age 8 with her father, a chemical engineer and her mother, a mathematician and working in computer software, she was raised with a strong interest in science as well as a passion for understanding preventative health. "I'm a family doctor, went to South Carolina (and) finished my practice residency, then I decided to do my second life which brought me back to Massachusetts to Harvard. Where I did my masters in public health because that's where I really realized I had to go back to that calling of preventative medicine." She goes on to say, " That was something that has been rooted in me, that's never really encouraged in most doctors' lives. You know, it's always -make a diagnosis- what's the treatment plan? What's the ICD code that you have to bill with, and how many people?... La la la la la. That's the world of healthcare. Ultimately, what people have to live with today. I was very fortunate also, not only did I have all of that as a background, I had a culture. My parents kept up with my language. I spoke five different languages when I came to this country."Dr. Uma discusses various experiences she had leading up to her "AHA" moment when she was with her mother who was dying of lung cancer for unbeknownst reasons, "she had seen a TV program and I could still hear her saying using ganja and I damn well knew what that word was. I beelined it and I heard her said they're using it for COPD, asthma, lung cancer, PTSD, and I still remember that" From there Dr. Uma has gone on to become one of only 50 physicians certified to practice cannabinoid medicine in the United States. She was one of High Times' top 50 females in Cannabis in 2019. I'll share one more quote to wrap up this intro, with the 3 key facts she shares when doing public speaking, and often she is told by doctors that they just didn't know this; "number one, nobody, and I use the word nobody because there are no deaths ever in the world from this medicine. You cannot die from it. You may feel like you're dying, you ain't gonna die from it. Fact number two, the government has a patent number 66 35 07, issued on October 7, 2003, and it's owned by the government. And it clearly states cannabinoids, not just one, cannabinoids, as an antioxidant. And guess what? A neuroprotectant. There's nothing here about the developing brain. There's nothing here about neurotoxicity. It says neuroprotectant, and they have known about it for Parkinson's, Alzheimer's, dementia, strokes, protection of the heart. They have known about it. Fact number three, doctors had the liberty to write prescriptions because it was allowed. And it was in the United States pharmacopeia from 1852 to 1942." Wow. Check out her website to learn more: http://totalhealthcarethc.com/Dr. Uma's Links:Facebook: https://www.facebook.com/profile.php?id=100008556311630Twitter: https://twitter.com/drumasaysInstagram: https://www.instagram.com/dr.uma_thc/LinkedIn: https://www.linkedin.com/in/dr-uma-dhanabalan-md-mph-faafp-mro-cms-02843040/Other links:https://necann.com/news/speaker/dr-uma-dhanabalan/https://hightimes.com/news/honorees-high-times-female-50/https://www.cancerschmancer.org/summit/https://www.linkedin.com/pulse/cannabinoid-medicine-rebirth-nature-dr-uma-dr-david-bearman/

This week on the Faculty Factory is an interview with Mithu Sen, MD, FRCPC, D'ABSM. Dr. Sen has been Acting Vice Dean of Faculty Affairs at Schulich School of Medicine & Dentistry, Western University in London, Ontario, Canada. Dr. Sen is also Assistant Dean, Faculty Equity and Wellness at Schulich School of Medicine & Dentistry. This is the first Faculty Factory podcast episode to take place with someone representing a Canadian institution. We look forward to having many more Canadian colleagues join us for interviews in the near future!

Samuel E. Cress, D.D.S., director of The Center for Craniofacial & Dental Sleep Medicine located in Sugar Land, Texas, received his Bachelor of Arts Degree from Austin College in Sherman, Texas. He completed his Doctorate of Dental Surgery from the University of Texas Health Science Center, San Antonio, Dental Branch. Dr. Cress also completed his residency in Dental Sleep Medicine at Tufts University School of Dental Medicine in Boston and his residency in TMD through the American Academy of Craniofacial Pain. In addition to his practice specializing in dental sleep medicine, TMD, cosmetic and Full Mouth Rehabilitation, Dr. Cress is a clinical instructor in the prestigious Dr. Dick Barns Group where he teaches other dentists the benefits of Airway Conscious Dentistry as well as diagnosis and treatment of patients suffering from TMD. He has successfully treated OSA and TMD patients since 2009 and he is a featured speaker at industry conferences and educational seminars. Dr. Cress pursues ongoing advanced education in the field of Dental Sleep Medicine, TMD, Cosmetic and Full Mouth Reconstructive Dentistry and currently holds a duel patent on an oral appliance for the treatment of OSA and TMD, currently undergoing FDA clearance. Dr. Cress has several published articles in the field of Dental Sleep Medicine. Dr. Cress recently presented at the TMJ Bioengineering Conference in Barcelona, Spain. Dr. Cress is a member of the American Academy of Dental Sleep Medicine, American Academy of Craniofacial Pain, American and Texas Dental Associations, the Academy of General Dentistry and the Greater Houston Dental Society. Dr. Cress has been in private practice in Sugar Land, Texas for 20 years and has been a family member of the prestigious Arrowhead Dental Lab since 1995. Dr. Cress and his wife, Kimberly Cress. M.D., director of the TMS Serenity Center for Depression, share their life with their son, Carter currently attending Hew Hampton School in New Hampshire.

The Stewart Center for Minimally Invasive Dental Medicine (formerly known as The Texas Center) was established in 2014. Co-founders, Dr. Hal Stewart and Dr. Craig Herre, saw both young and established dentists who were frustrated with the current state of their practices. It was their desire to create a comprehensive course that would give doctors a logical, step by step approach to rehabilitating even the most broken-down dentition while staying free of the limitations put on them by insurance companies. Teaching minimally invasive techniques was also a priority. Our goal at The Stewart Center is to provide an intimate learning setting for the dental professional who wants to:  Profoundly impact their patients’ health in a significant way. The opportunity to practice in an insurance, third-party free environment. Acquire the confidence and ability to diagnose, treat, and restore failing dentitions in a systematic and predictable way.  To learn state-of-the-art minimally invasive techniques. https://vimeo.com/275886940

  Welcome to another episode of Biotechnology Focus radio! I am your host – Michelle Currie – here to give you the Canadian biotech rundown from coast to coast. This week there has been some revolutionary research in HIV, and natural killer cells. FACIT – the fight against cancer innovation trust – has invested in three novel cancer therapeutic discoveries, and Oncolytics Biotech enters a clinical collaboration to combat breast cancer. Keep listening to find out more details!  +++++  Researchers at the BC Centre for Excellence in HIV/AIDS (BC-CfE) and Simon Fraser University (SFU), in partnership with University of British Columbia (UBC) and Western University, develop a way of dating “hibernating” HIV strains, in an advancement for HIV cure research in the province.  Published in the prestigious journal Proceedings of the National Academy of Sciences (PNAS), the BC-CfE’s first major scientific contribution to the area of HIV cure research confirms that dormant HIV strains can persist in the body for decades.  Dormant HIV strains, embed their DNA into the body’s cells, tucking themselves away for years – but can reactivate at any time – and are unreachable by antiretroviral treatments and the immune system. This is the reason why HIV treatment needs to be maintained for life.  Dr. Zabrina Brumme, director, Laboratory with BC Centre for Excellence in HIV/AIDS and lead author on the study says that, “If you can’t identify it, you can’t cure it. This research provides further essential clues in the pursuit of an HIV cure—which will ultimately require the complete eradication of dormant or ‘latent’ HIV strains. Scientists have long known that strains of HIV can remain essentially in hibernation in an individual living with HIV, only to reactivate many years later. Our study confirms that the latent HIV reservoir is genetically diverse and can contain viral strains dating back to transmission.”  Dr. Julio Montaner, director of the BC Centre for Excellence in HIV/AIDS  says that, “The BC Centre for Excellence in HIV/AIDS  has consistently been a national and global leader on research on HIV and on the implementation of its pioneering Treatment as Prevention® strategy. The addition of molecular biologist Dr. Zabrina Brumme as director of the innovative BC Centre for Excellence in HIV/AIDS Laboratory ensures the BC Centre for Excellence in HIV/AIDS  will play a significant role in HIV cure research. Curative strategies will need to address this new study’s key findings. I want to acknowledge the study participants and thank them for helping to increase our knowledge on the origins of the latent HIV reservoir.”  Brad Jones, a Ph.D. student with the University of British Columbia (UBC) at BC Centre for Excellence in HIV/AIDS and the first author on the study says that, “By creating family trees of viruses using a technique called molecular phylogenetics, we can reconstruct the evolutionary history of HIV within a person. In essence, we created a highly calibrated ‘time machine’ that gives us a specific time stamp for when each dormant HIV strain originally appeared in a person.”  Through advances in antiretroviral therapy, an individual living with HIV can now live a longer, healthier life on treatment. Treatment works by stopping HIV from infecting new cells. On sustained treatment, individuals can achieve a level of virus that is undetectable by standard blood tests. An undetectable viral load means improved health and that the virus is not transmittable to others—the concept behind Treatment as Prevention®.  Dr. Jeffrey Joy, research scientist at the BC Centre for Excellence in HIV/AIDS and co-author on the study says that “Previous research had already revealed that the HIV reservoir was genetically complex. With our method, we can now understand that complexity with greater granularity, pinpointing exactly when each unique HIV strain originally appeared in a person.”  Dr. Art Poon, assistant professor at Western University’s Schulich School of Medicine & Dentistry, also a co-author on the study, says that, “In order to eradicate HIV from a person’s body, you first need to know the characteristics of HIV in the latent reservoir. We are providing a method for better measuring the timeline of virus latency and evolution within an individual living with HIV.”  “Dating” dormant HIV strains within the viral reservoir involve comparing them to strains that evolved in an HIV-positive person over their entire history of infection.  The BC Centre for Excellence in HIV/AIDS is one of a handful of institutions worldwide capable of such research, thanks to its maintenance of a historical repository of blood specimens from individuals diagnosed with HIV in BC. These specimens date back to 1996 and were originally collected for viral load and drug resistance testing. The BC Centre for Excellence in HIV/AIDS Laboratory has provided HIV drug resistance genotyping for virtually all Canadian provinces and territories since 1998, as well as for many countries worldwide.  This research was funded by the Canadian Institutes of Health Research (CIHR) in partnership with the Canadian Foundation for AIDS Research (CANFAR) and the International AIDS Society (IAS) through its support of the Canadian HIV Cure Enterprise (CanCURE), as well as the US National Institutes of Health (NIH) through its support of the Martin Delaney BELIEVE Collaboratory.  +++++  Immune checkpoint inhibitors are waging a revolutionary war on cancer, but new research challenges the central dogma of how this drug treatment works. This research, published in the prestigious Journal of Clinical Investigation, shows for the first time that often-overlooked immune cells called Natural Killer (NK) cells play a crucial role in responding to checkpoint inhibitors.  co-senior author Dr. Michele Ardolino, a scientist at The Ottawa Hospital and assistant professor at the University of Ottawa  explains that, “Checkpoint inhibitors work by waking up the body’s own immune system and unleashing an immune attack on cancer cells. For many years, everyone assumed that checkpoint inhibitors targeted immune cells called T-cells. But our research shows that they also target Natural Killer cells and these cells play a key role in the how this treatment works.”  Dr. Arolino led the study together with Dr. David Raulet, a professor at the University of California at Berkeley.  Dr. Raulet says that “In the cancer immunotherapy field there has been a singular focus on mobilizing anti-tumor T-cells. We believe that NK cells have an important place at the table. Checkpoint therapy combined with other NK-directed immunotherapies may enable us to target many types of tumours that are currently non-responsive to available therapies.”  T-cells and Natural Killer cells can both recognize and kill cancer cells, but they do so in very different ways. NK cells recognize patterns of changes on cancer cells and are the immune system’s first line of defense. A T-cell, on the other hand, recognizes a single abnormal molecule on a cancer cell and initiates a more focused attack.  In the current study, Drs. Ardolino, Raulet and their colleagues investigated the effect of checkpoint inhibitors in various mouse models of cancer. They found that checkpoint inhibitors could shrink tumours even in mice with no anti-cancer T-cells, meaning that some other kind of cell must be responding to the checkpoint inhibitors. When the mice were depleted of Natural Killer cells, it greatly reduced or eliminated the anti-cancer effect of the checkpoint inhibitors. They also showed that Natural Killer cells produce the same checkpoint receptor molecules that T cells do, inferring they can respond directly to checkpoint inhibitors.  co-lead author Jonathan Hodgins, a PhD student at The Ottawa Hospital and the University of Ottawa says that, “This research helps solve a mystery that’s been seen in the clinic, where certain cancers are very susceptible to checkpoint inhibitors even though their T-cells don’t seem to be activated. If we’re right, Natural Killer cells are probably being activated in these patients.”  Previously, Dr. Ardolino, worked in Dr. Raulet’s lab in California before he was recruited to The Ottawa Hospital and the University of Ottawa in 2016. Together they are now investigating approaches to further enhance the cancer-killing ability of Natural Killer cells.  Dr. Ardolino says that, “My dream is that when people come to the hospital with cancer, we’ll be able to take a biopsy and determine not only the mutations in their cancer, but also profile how their immune system is interacting with their cancer. Then we would give the patient the immunotherapy treatments that is most likely to work for them.”  +++++  As a gateway to the cancer research pipeline in Ontario, and a bridge between public and private sectors with an expanding portfolio of breakthrough innovations, Fight Against Cancer Innovation Trust (FACIT) is committed to supporting Ontario entrepreneurs through the latest round of its Prospects Oncology Fund to continuously identify and advance breakthroughs in science and technology.  FACIT has carefully chosen three novel cancer therapeutic discoveries to receive early-stage capital – biotechnology start-up Talon Pharmaceuticals, the Drug Discovery team at the Ontario Institute for Cancer Research (OICR) and the Centre for Commercialization of Regenerative Medicine (CCRM).  The Prospects Fund provides entrepreneurial scientists with the capital resources necessary to achieve critical proof-of-principle studies for their cutting-edge breakthroughs aiming to benefit future patients.  Talon Pharmaceuticals, through its Multiphore drug design platform, is focused on the discovery, development, and commercialization of medicines designed to save lives and improve patient quality of life. They are developing a novel series of small molecules with an undisclosed mechanism of action applying decades of experience with central nervous system (CNS) drug discovery.  OICR is a collaborative, not-for-profit research institute accelerating the development of new cancer research discoveries for patients around the world while maximizing the economic benefit of this research for the people of Ontario. OICR’s Drug Discovery team and their collaborators at the National Research Council (NRC) will receive funds towards the development of a potentially superior class of antibody-drug conjugates.  CCRM’s mission is to generate sustainable health and economic benefits through global collaboration in cell and gene therapy, and regenerative medicine. CCRM will receive funds towards the development of a universally compatible source for the next generation of CAR-T therapies.  FACIT’s $35-million in investments over multiple years addresses a critical health care seed-stage gap often experienced by Ontario product developers. De-risking innovation sets up successful projects for either company creation or a larger round of financing by FACIT and its investment partners, with over $340-million in follow-on financings to date. FACIT’s maturing portfolio of technology investments anchors companies and jobs in Ontario and reduces the need for entrepreneurs to look south of the border.  David O’Neill, president of FACIT  says that, “Our team is pleased to invest in and work alongside these entrepreneurial scientists, providing capital, industry networks and commercialization expertise, as they advance their therapies closer to clinical development. Capitalizing on the province’s investment in healthcare and scientific collaboration through our strategic partners at OICR is not only good for creating high-skilled jobs but also ensures research undergoes translation to impact the lives of patients with cancer.”  +++++  Oncolytics Biotech Incorporated enters into a clinical collaboration with SOLTI, an academic research group dedicated to clinical and translational research in breast cancer. This clinical collaboration, being sponsored by Oncolytics and facilitated by SOLTI, is a window of opportunity study in the neoadjuvant setting for breast cancer.  Reolysin, (pel-areo-rep), an intravenously delivered immuno-oncolytic virus turning cold tumours hot is under development by Oncolytics Biotech. Patients will receive the appropriate standard of care for their cancer subtype plus pel-areo-rep (or Reolysin with or without the anti-PD-L1 cancer immunotherapy ate-zoli-zu-mab (also known as Tecentriq)). Patients are biopsied on day one, followed immediately by treatment and a final biopsy after three weeks, on the day of their mastectomy. Data generated from this study is intended to confirm that the virus is acting as a novel immunotherapy and to provide comprehensive biomarker data by breast cancer sub-type, to support Oncolytics’ phase 3 study in metastatic breast cancer and is expected in mid 2019.  Matt Coffey, president and CEO of Oncolytics Biotech says that they are thrilled to enter into this collaboration with SOLTI and sponsor this window of opportunity study.  They expect that this study will provide additional biomarker and immunological data to support our planned phase three study in metastatic breast cancer. This data should confirm the findings of our phase two study and generate a robust biomarker plan designed to potentially enhance our phase three program. Importantly, it will also generate additional data demonstrating how the promotion of a virally induced inflamed phenotype should synergise with checkpoint inhibitors targeting PD-L1 like ate-zoli-zu-mab.”  The study, facilitated by SOLTI, will be coordinated by Dr. Aleix Prat, head of Medical Oncology at the Hospital Clínic of Barcelona, associate professor of the University of Barcelona and the head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Group at August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and member of Oncolytics’ Scientific Advisory Board. SOLTI has a network of more than 300 professionals, mostly medical oncologists, in over 80 hospitals in Spain, Portugal, France, and Italy. Final study design and other details will be announced upon enrollment of the first patient, expected around the end of 2018 or very early 2019.   Dr. Prat says that, “It has been demonstrated that when reovirus infects a tumor, it promotes the release of immuno-stimulatory signals. This, in turn, results in the upregulation of PD-L1 on tumor cells and the recruitment of inflammatory immune cells like Natural Killer-cells and cytotoxic T-cells to the tumor, which are required prerequisites for checkpoint inhibitors to function effectively.  In short, it turns cold tumours hot. They believe pel-areo-rep can demonstrate the necessary inflamed tumour phenotype to prime tumours for PD-L1 blockade, which could potentially represent a promising form of cancer immunotherapy combination with ate-zoli-zu-mab. Results from this study will seek to establish the virus as an important immuno-oncology agent in breast cancer, which could ultimately support the expansion of pel-areo-rep beyond metastatic breast cancer into first-line therapy.”  +++++  Well that wraps up another episode of Biotechnology Focus radio. Thanks for listening! Make sure to check out the articles on the website: biotechnologyfocus.ca. Until the next time, from my desk to yours – this is Michelle Currie.

Welcome to another episode of Biotechnology Focus radio. I am your host – Michelle Currie – here to give you the rundown on the Canadian biotech scene! Coming up we have some inspiring research from the University of Alberta regarding viral pathogen treatment; McMaster researchers have a new hypothesis on Huntington’s Disease; RepliCel solidifies co-development deal in Greater China; scientists discover a way to genetically screen for acute myeloid leukemia; and putting Canada in the limelight when it comes down to artificial intelligence and deep learning.   Keep on listening to find out more of the details!  +++++  The University of Alberta appears to have hit the nail on the head yet again. With so much inspiring research coming out of this campus, it should come as no surprise that they have made a significant discovery that has the potential to treat viral pathogens such as the Zika virus and respiratory syncytial virus (RSV).  Scientists from UofA discovered a new and promising class of chemical compounds that is comparable to the naturally occurring isatisine A, an antiviral originally found in traditional Chinese herbal medicine.  Fred West, a professor in the Department of Chemistry, who led the discovery along with RSV researcher David Marchant, a professor in the Department of Medical Microbiology and Immunology, says, “This is both a remarkable scientific discovery and also something that has the potential to positively affect not only global health but also the economy of Canada.”   West and Marchant worked in conjunction with Zika expert and cell biologist Tob Hobman, who is also a professor in the Faculty of Medicine & Dentistry at the University of Alberta. They tested the compound against potent viruses, such as Zika and respiratory syncytial virus , that yielded remarkable results. The compound was active and effective against both viral infections.  The Zika virus, which is a mosquito-borne pathogen, began wreaking havoc in May of 2015 after it had been identified as the culprit behind an outbreak of prenatal defects across South America. It coincided with a 2,700 per cent increase in Brazil from reported cases of microcephaly, an often fatal congenital condition associated with incomplete brain development in newborns.  Whereas, relatively unheard of respiratory syncytial virus poses a greater threat to infants, the elderly and those with compromised immune systems. This virus is responsible for up to 30 per cent of hospitalized respiratory cases in any given year.   West adds, “What we aim to do is further refine this compound to keep the elements that make it medically active and build in the structural components that make it possible for patients to consume in drug form. We are approaching that point.”  The next stage of drug development is already underway, and with Marchant’s new company Antibiddes Technologies Inc. ready to license the intellectual property and begin commercialisation, this is a promising development that could change the face of viral pathogen treatment.  ++++++  McMaster researchers develop a new theory regarding Huntington’s Disease that may shape the future of drug development for the disease.  A team of researchers from the university found that a unique type of signalling found in damaged DNA signals huntingtin – a harmful mutant protein found in the genes of those diagnosed with Huntington’s Disease – to aid in DNA repair is defective for those with the condition.  The new hypothesis was published in the Proceedings of the National Academy of Science (PNAS).  Laura Bowie, a PhD student in the Department of Biochemistry and Biomedical Sciences at McMaster, says, “The concept was that if we applied the signalling molecule back in excess, even orally, this signalling can be restored in the Huntington’s disease mouse brain. The net result was that we fixed the modification of huntingtin not seen in mutant huntingtin in Huntington’s disease.”  Using this hypothesis, the study team discovered a molecule called N6-furfuryladenine, derived from the repair of DNA damage, which corrected the defect seen in mutant huntingtin.  “Based on dosing by different ways of this molecule in mouse Huntington’s disease models, Huntington’s disease symptoms were reversed,” says Bowie. “The mutant huntingtin protein levels were also restored to normal, which was a surprise to us.”  Ray Truant, senior author on the study, has dedicated his career to Huntington’s disease research and how mutation leads to Huntington’s disease. It was his lab that was the first to demonstrate that normal huntingtin was involved in DNA repair.  Truant argues that the traditional and controversial amyloid/protein misfolding hypothesis, where a group of proteins stick together forming brain deposits, is likely the result of the disease, rather than its cause.  He also stated that he considers this paper the most significant of his career, and that “This is an important new lead and a new hypothesis, but it is important for people to know this is not a drug or cure. This is the first new hypothesis for Huntington’s disease in 25 years that does not rely on the version of the amyloid hypothesis which has consistently failed in drug development for other diseases.”  Huntington’s Disease is an inherited, neurodegenerative illness that comes with dire physical, cognitive and emotional symptoms that often hit around middle age. The mutant huntingtin protein causes certain parts of the brain to die – specifically the caudate, the putamen and, as the disease progresses, the cerebral cortex.  Bev Heim-Myers, CEO of the Huntington Society of Canada adds “Innovative research initiatives, such as the work led by the team in Dr. Truant’s lab, including PhD student Laurie Bowie, has the potential to transform HD research. The answers we find for Huntington’s disease will likely lead to better understanding of treatments for other neurological diseases and it is important that we continue this cross-talk amongst neurodegenerative diseases.”  The study was conducted in partnership with the University of Alberta, Western University, Johns Hopkins University, and a collaboration with a U.S. biotech firm, Mitokinin LLC. Their work now continues in developing better derivatives of N6-furfuryladenine towards developing a drug.  This study was funded by the Canadian Institutes of Health Research, the Krembil Foundation, and the Huntington Society of Canada.  +++++  Vancouver-based Replicel Life Sciences announces that they have signed definitive agreements with YOFOTO, a Chinese company, solidifying their partnership to commercialise three of Replicel’s programs in Greater China.    The collaboration focuses on the development and commercialization in Greater China of RepliCel’s tendon regeneration cell therapy (RCT-01), skin rejuvenation cell therapy (RCS-01), and its injection technology in development for dermal applications (RCI-02) (excluding hair-related treatments).  YOFOTO Chairman states, “YOFOTO is a fast-growing company built on values related to beauty and healthy, active lifestyles. As a key part of developing and commercializing products related to these core values for our consumers, we are committed to being a leader in China in the commercialization of regenerative medicines.  The RepliCel cell therapy and injection technologies focused on skin rejuvenation and tendon repair are important building blocks in YOFOTO’s strategic healthcare vision. We are pleased to have structured a deal with RepliCel which results in YOFOTO not only being a development partner and commercial licensee but also an investor committed to contributing to RepliCel’s global success.”  YOFOTO’s investment in Replicel will include milestone payments, minimum program funding commitments, and sales royalties in exchange for an exclusive 15-year license to three of RepliCel products for Greater China (Mainland China, Hong Kong, Macau, and Taiwan). Additionally, YOFOTO commits to spending a minimum of C$7 million on Replicel’s programs and associated cell processing manufacturing facility over the next five years in Greater China.  RepliCel president & CEO, Lee Buckler says, “In 2017 RepliCel delivered successful phase I data in all three of its cell therapy programs and functioning prototypes of its next-generation dermal injector,” says “We were committed to delivering a landmark partnership to RepliCel shareholders in 2018. The partnership with YOFOTO represents such a deal and provides RepliCel with not only an outstanding partner in Greater China but capital to move our programs forward in Europe and North America,” he adds.  The deposit of over $5 million has been paid by YOFOTO, but remains in escrow following the closing of the transaction. Once YOFOTO has met certain conditions and once relevant Chinese patents are issued in China, they will be assigned a YOFOTO-owned Canadian subsidiary.  This is very exciting news for Replicel and Canada alike, as Canadian biotech companies begin to spread across the Pacific, with more foreign companies seeking to invest in Canadian innovation and research.  +++++  An international team of scientists discovers a technique that predicts healthy individuals who are at risk of developing acute myeloid leukemia (AML), which is an aggressive and often deadly form of blood cancer.  The findings, published in Nature, illuminate the ‘black box of leukemia’ and answer the question of where, when and how the disease begins, says co-principal investigator Dr. John Dick, Senior Scientist at Princess Margaret Cancer Centre, University Health Network.  Dr. Dick, who is a professor, Department of Molecular Genetics, University of Toronto, holds the Canada Research Chair in Stem Cell Biology, and is co-leader of the Acute Leukemia Translational Research Initiative at the Ontario Institute for Cancer Research, says, “We have been able to identify people in the general population who have traces of mutations in their blood that represent the first steps in how normal blood cells begin on a pathway of becoming increasingly abnormal and puts them at risk of progressing to acute myeloid leukemia. We can find these traces up to 10 years before acute myeloid leukemia actually develops. This long-time window gives us the first opportunity to think about how to prevent acute myeloid leukemia.”  Study author Dr. Sagi Abelson, a post-doctoral fellow in the Dick lab, says: “acute myeloid leukemia is a devastating disease diagnosed too late, with a 90 per cent mortality rate after the age of 65. Our findings show it is possible to identify individuals in the general population who are at high risk of developing acute myeloid leukemia through a genetic test on a blood sample. The ultimate goal is to identify these individuals and study how we can target the mutated blood cells long before the disease actually begins.”  The study stems from Dr. Dick’s 2014 discovery that a pre-leukemic stem cell could be found hiding amongst all the leukemia cells that are present in the blood sample taken when a person is first diagnosed with acute myeloid leukemia. The pre-leukemic stem cell still functions normally but it has taken the first step in generating pathway of cells that became more and more abnormal resulting in acute myeloid leukemia (Nature, February 12, 2014).  Dr. Dick says, “Our 2014 study predicted that people with early mutations in their blood stem cells, long before the disease appears and makes them sick, should be able to be detected within the general population by testing a blood sample for the presence of the mutation.”  The team extracted the data from more than 100 participants who developed acute myeloid leukemia six to 10 years after joining the study, plus the data from an age-matched cohort of more than 400 who did not develop the disease.  Dick adds, “We wanted to know if there was any difference between these two groups in the genetics of their ‘normal’ blood samples taken at enrollment. To find out, we developed a gene sequencing tool that captured the most common genes that get altered in acute myeloid leukemia and sequenced all the 500 blood samples.”  The gene sequencing tool was a success and picked up mutations years before an individual was diagnosed with acute myeloid leukemia to accurately predict those at risk. Moreover, the team used advanced computational technology to assay the information obtained from routinely collected blood tests taken over 15 years in Israel and housed in a massive database of 3.4 million electronic health records.  The study has linked acute myeloid leukemia with a common feature of aging called ARCH-age related clonal hematopoiesis, whereby blood stem cells acquire mutations and become a little more proliferative. The majority of people that have ARCH will not develop acute myeloid leukemia. It is a requirement to have acute myeloid leukemia, but not the other way around.  +++++  Machine learning is augmenting human ability and drastically changing possibilities. It is restructuring businesses and rewiring brains for transformative thinking. Whether it be to develop vaccines for deadly diseases or combat climate change, Canada is at the forefront of this monumental shift.  Canada has been on the vanguard of machine learning long before it became a popular headline. The growth and brilliant minds from around the country have led the way for Canada to place its mark with AI on the world and build a more promising ecosystem for the future.  Across the country, there have been several companies lending a hand in this newer and multi-faceted industry that will reshape history. Among those, innovative researchers are developing imaging devices for skin cancer, diagnostic platforms that analyse natural speech to detect dementia and mental decline, advanced signal analysis to diagnose coronary artery disease, just to name a few, and numerous others that stem to topics unrelated to health care, but keep Canada at the forefront of change.  This year Canada had its 31st Canadian Conference in Artificial Intelligence that stands to show how long Canada has been involved with this game-changing technology. Events like this bring together hundreds of leaders in research, industry, and government that provide a melting pot of inquisitive and like-minded people.  Life sciences is an industry that is filled with innovation and offers much economic promise for governments who desire to grow a knowledge-based economy. Therefore, Biotechnology Focus, in support of Global Biotech Week, is conducting a survey to gauge Canada’s innovation culture. The results will be featured in a special report in the September issue.  The report will highlight trends, identify areas of strengths that can be leveraged as well as opportunities for improvement to support growth for the Canadian life sciences industry.  Artificial intelligence and deep learning have the potential to revolutionize healthcare, and with Canada as a global frontrunner, we can expect to see exponential shifts in the upcoming years to come.  Add your voice to the survey at https://www.surveymonkey.com/r/BioFocus2018.   ++++++  Well, that wraps up another episode of Biotechnology Focus radio! Thanks for tuning in! And let’s remember that with Canada in the limelight it is important for everybody in the life sciences industry to make their voice heard, so please fill out the quick innovation survey so we can continue to enhance this spectacular industry and elevate health care. Until next time, from my desk to yours – this is Michelle Currie.  

Concussion Corner is your trusted resource for interdisciplinary conversations related to all things concussion-related in healthcare, advocacy, and sport. *This podcast is for entertainment purposes only and should not be confused for medical advice. Please reach out to your medical team or call 911 if this is an emergency*Check us out on Facebook, Instagram, Twitter, & YouTube

Dr. Kristine Josef is a Neurologic Clinical Specialist with experience working in various areas including adult inpatient rehabilitation and acute care. While working in acute care, she was involved in the Early Mobility project in the intensive care unit that resulted in patient decreased length of stay, decreased hospital costs, and increased incidence of patient discharge home vs post-acute facilities. She has given multiple presentations on the topic of delirium. Recently, she co-authored a poster that was presented at the 2017 Combined Sections Meeting in San Antonio, TX that was titled “Delirium in patients with cerebrovascular accident: increasing treatment team awareness.” Her doctorate in physical therapy is from the University of Medicine & Dentistry of New Jersey, which now is Rutgers University. She is a board certified neurologic clinical specialist through the American Board of Physical Therapy Specialties. In this interview, she discusses: distinguishing delirium from encephalopathy; tools for accurate delirium screening and diagnosis in critically ill patients; the role physical therapy plays in dealing with the problem of patients with delirium from the standpoint of diagnosis and treatment; if anything can be done pre-surgically to prevent the occurrence of delirium; aging and co-morbidities in relation to delirium; the role of family members in changing the course of delirium in a patient; and the advantages and disadvantages of using physical restraints to manage behavioral symptoms of hospitalized patients.    

Dr. Dallas Kingsbury is accredited in sports medicine by the Accreditation Council for Graduate Medical Education as an instructor in the Rusk Rehabilitation department at NYU Langone Medical Center. He has an interest in interventional sports and regenerative medicine and has had the unique experience of working with the performing arts, aerial acrobatics, and flying trapeze communities. It also is worth mentioning that he is particular adept himself as a man in the flying trapeze. Dr. Kingsbury combines his interest in treating patients with an involvement in clinical research pertaining to osteoarthritis, knee injections, and the treatment of chronic tendon problems. His medical degree is from the University of Medicine & Dentistry and he did his residency at the Icahn School of Medicine at Mount Sinai, Rehabilitation Medicine.   In this interview, Dr. Kingsbury discusses the kinds of patients he treats for musculoskeletal conditions, reasons for patient delays in seeking​ treatment, patient resilience and willingness to participate actively in all aspects of rehabilitation, role of being overweight plays in onset of musculoskeletal health problems, how outcomes are affected by time between occurrence of injury and provision of treatment, smartphone usage as a cause of musculoskeletal problems, and translation of clinical research to bed site care.

Thanks for tuning into the Healthy Wealthy and Smart Podcast! I had the pleasure of chatting with Mike Connors about advocacy in physical therapy. Mike is a private practice physical therapy owner, an outside consultant for a professional ballet company in Fort Worth and an adjunct professor in orthopaedic physical therapy for the DPT program at the University of North Texas Health Science Center. In addition, Mike is the current President of the Texas Physical Therapy Association advocating regularly for the PT profession in Austin and DC on regulatory and payment policy issues impacting PT. In this episode, we discuss: -Levels of advocacy and ways to demonstrate the efficacy of physical therapy -Mike’s pitch for APTA membership -Mike’s initial wellness consultation and his focus on preventative care -Advice to new professionals on empathy and preventing burnout -And so much more!   Mike stresses the need for PT advocacy which can take many forms including calling an insurance company, talking to medical colleagues, and increasing awareness in the community in addition to legislative change. He states, “What did you do today that was in the patient’s best interest that the patient couldn’t do for themselves or didn't have the knowledge or the resources to do for themselves? We treat patients. We manage their complex presentations, but we do a lot more than I think we give ourselves credit for. That's a big part of why it is we don't have the widespread knowledge base about what we do because we don’t talk enough about what we do. PT has become the new fight club and the #1 rule of PT is not to talk about PT.”   Mike believes there are untapped candidates for physical therapy services due to public unawareness of the healthcare benefits. “Ironically, in private practice, we are sitting here all competing against one another for 20% of the pie and what we’re not seeing is another 75+% that’s out there that’s doing everything but physical therapy.”   Mike encourages entrepreneurship within physical therapy and recommends to continually strive for excellence. Mike advices, “Entrepreneurs are going to continually learn and evolve over time. Count your successes as much as you count your failures as long as you learn from them and you evolve then it was a worthwhile endeavor.”   For more about Mike: Mike has a BS in Biology from Stockton College with a minor in Psychology (2001). His entry level degree in physical therapy is a Master of Physical Therapy from University of Medicine & Dentistry of NJ-Rutgers University (2003). Mike has a post professional Doctor of Physical Therapy degree from Temple University (2008). He became a board certified specialist in Orthopaedic Physical Therapy from the American Board of PT Specialties in 2011. Mike is currently finishing (ABD) the remaining requirements for completion of a PhD degree in Physical Therapy with an emphasis in applied biomechanics from Texas Woman's University (Anticipated completion 2016).   Mike began working with GTC in October 2004. He most recently rejoined the GTC family in June 2015 as the Director of the Fort Worth Clinic.   Mike's focus and specialization in orthopaedic physical therapy makes him an efficient clinician in managing patients with orthopedic dysfunction. He utilizes a multimodal approach to meet the needs of his patients and clients that include spinal manipulation, dry needling, KT taping, and various other interventions. Mike is certified in functional dry needling from Kinetacore. He has experience working with patients of all ages, from kids to adults and from the weekend warrior to the elite athlete. He is an outside consultant for a professional ballet company in Fort Worth and is an adjunct professor in orthopaedic physical therapy for the DPT program at the University of North Texas Health Science Center. In addition, Mike is the current President of the Texas Physical Therapy Association advocating regularly for the PT profession in Austin and DC on regulatory and payment policy issues impacting PT.   Mike is happily married to his wife Shannon. He enjoys spending time with his family, that includes two beautiful daughters. Mike enjoys staying active, running, traveling, exercising, biking, golfing and staying active in his faith community.   Personal statement: It's ALWAYS all about the patient. We exist as PTs to help patients move better with less pain. It's my pleasure to help patients achieve this goal on a day to day basis.   Social Media: Greater Therapy Centers Twitter Facebook   Thanks for listening and subscribing to the podcast! Make sure to connect with me on twitter and facebook to stay updated on all of the latest! Show your support for the show by leaving a rating and review on iTunes!   Have a great week and stay Healthy Wealthy and Smart!   Xo Karen   P.S. Do you want to be a stand out podcast guest? Make sure to grab the tools from the FREE eBook on the home page! Check out my latest blog post on The Do's and Don'ts of Social Media!   P.S.S. Check out the inaugural Women in PT Summit here! Sign up now as space is limited!

In this episode of Pharma Talk Radio, we feature medical oncologist, Dr Anna Pavlick, Director of the Melanoma Program at the NYU Cancer Institute on Safety Elements of Cancer Immunotherapies. Dr Pavlick originally gave this presentation in June 2015 at the IO360 conference.  Her talk focuses on immune related adverse affects of immuno therapy. More specifically, she covers: •    Identifying warning signs and low threshold for workup and treatment •    Understanding “pseudoprogression” before response, delayed toxicities •    Reporting and assessing adverse effects during clinical trial phases •    How to predict safety concerns when moving from animal models to human trials We are pleased to bring this session to the public to help researchers, doctors, patients and care givers with some information on immune related adverse affects of immuno therapy. Please note that Dr Pavlick does occassionally refer to slides which are not included in the recording of this session. Anna Pavlick, DO, MD is the Director of the NYU Cancer Institute Melanoma Research Program. After finishing her studies at University of Medicine & Dentistry of New Jersey, School of Osteopathic Medicine, Dr Pavlick completed her residency in internal medicine and her fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. In 1999, she went on to become the Director of Clinical Oncology at UMDNJ in New Jersey before coming to NYU. The next IO360 conference will take place February 2-3, 2016 at the New York Academy of Medicine in NYC. For more information, visit www.theconferenceforum.org.   

Michael Strong, Dean, Schulich School of Medicine & Dentistry, Distinguished University Professor, Western University, Rix Clinical Skills Learning Building, London - CANADA speaks on miRNA modulation of NEFL mRNA stability in ALS - RNA Metabolism: Changing Paradigms in Neurodegeneration” This seminar has been recorded at Area Science Park Trieste by ICGEB Trieste

Monday, May 9, 2011 - Our incredible special guest is Ira Shoulson, MD Professor of Neurology, Pharmacology and Human Science and Director of the Program for Regulatory Science and Medicine (PRSM) at Georgetown University – new full-time academic positions effective January 1, 2011.  Previously, Dr Shoulson was the Louis C. Lasagna Professor of Experimental Therapeutics and Professor of Neurology, Pharmacology and Medicine at the University of Rochester School of Medicine & Dentistry in Rochester, New York.  He received his MD degree (1971) and postdoctoral training in medicine (1971-73) and neurology (1975-77) at the University of Rochester and in experimental therapeutics at the National Institutes of Health (1973-75).  Dr. Shoulson founded the Parkinson Study Group (www.parkinson-strudy-group.org) in 1985 and the Huntington Study Group (www.huntington-study-group.org) in 1994 -- international academic consortia devoted to research and development of treatments for Parkinson's disease, Huntington's disease and related neurodegenerative and neurogenetic disorders.  He has served as principal investigator of the National Institutes of Health-sponsored trials "Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism" (DATATOP), the “Prospective Huntington At Risk Observational Study” (PHAROS), and more than 25 other controlled multi-center studies.  He was formerly a member of the National Institute of Neurological Disorders and Stroke Council and president of the American Society for Experimental NeuroTherapeutics (ASENT) He is currently associate editor of Archives of Neurology and a member of the Institute of Medicine of the National Academy of Sciences.  He has authored over 280 scientific reports. 

Guest: Marco A Zarbin, MD, PhD, FACSAlfonse Cinotti, MD/Lions Eye Research Professor ChairInstitute of Ophthalmology & Visual ScienceNew Jersey Medical SchoolUniversity of Medicine & Dentistry of New JerseyNewark, NJ

p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 13.0px 'Lucida Grande'} Guest: Marco A Zarbin, MD, PhD, FACS Alfonse Cinotti, MD/Lions Eye Research Professor  Chair Institute of Ophthalmology & Visual Science New Jersey Medical School University of Medicine & Dentistry of New Jersey Newark, NJ 

Guest: Marco A Zarbin, MD, PhD, FACS Alfonse Cinotti, MD/Lions Eye Research Professor  Chair Institute of Ophthalmology & Visual Science New Jersey Medical School University of Medicine & Dentistry of New Jersey Newark, NJ

Guest: Marco A Zarbin, MD, PhD, FACS Alfonse Cinotti, MD/Lions Eye Research Professor  Chair Institute of Ophthalmology & Visual Science New Jersey Medical School University of Medicine & Dentistry of New Jersey Newark, NJ